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ABSTRACT

Cui, Yi. Ph.D., Purdue University, May 2016. Approaching DNA Methylation at the Nanoscale. Major Professor: Joseph Irudayaraj.

Epigenetics involves a variety of biochemical modifications occurring on chromatin
that are able to regulate and fine-tune genetic activities without altering the underlying
DNA sequence. So far, four types of epigenetic modulation have been extensively studied:
DNA methylation, histone post-translational modification, non-coding RNA, and nuclear
organization. A fast-growing body of evidence suggests that epigenetic mechanism plays
a fundamental role in physiology and pathology. Of the elucidated epigenetic processes,
DNA methylation is the one under intense research due to its direct impact on gene expression, which dynamically bridges the microscale genotype and macroscale phenotype.
However, to date our understanding of DNA methylation has primarily come from ensemble and end-point measurements using a population of cells or bulky samples. Unlike
genetic aberrations (e.g., amplification, deletion, translocation, and mutation) that are rare
to occur and resistant to reverse, events relating to epigenetic modifications take place in
a time- and context-dependent manner, thus necessitating nanoscale tools to dissect epigenetic dynamics at a finer spatiotemporal resolution. In my Ph.D. work, a group of advanced single-molecule fluorescence tools, in addition to methodologies in bioengineering, nanotechnology, molecular biology, and bioinformatics, is implemented to approach

xx
the DNA methylation-related activities. Furthermore, part of my research aims to translate the new discoveries from single-cell experiments to biomedical applications. Another
focus of my dissertation is on effective manipulation of DNA methylation by novel techniques including nanomaterials and optogenetics. Taken together, these efforts lay the
groundwork for better understanding of DNA methylation and provide ample avenues for
improving epigenetic therapies.
After the introduction chapter, the second and third chapters of my dissertation center on elucidating the behavior of MBD3 protein within a single living cell, in order to
infer the real-time dynamics of DNA methylation. Taking use of fluorescence correlation
spectroscopy (FCS), fluorescence lifetime imaging (FLIM), Förster resonance energy
transfer (FRET), and photon counting histogram (PCH), the in situ binding preference,
dissociation kinetics, and stoichiometric transition of MBD3 were probed with unprecedented precision. Due to the substitution of two amino acids in its DNA-binding motif,
MBD3 has evolved to differ from other MBD homologues in physicochemical properties
as well as in biological functions. Consequently, its altered binding affinity and specificity with DNA methylation lead to unique molecular behaviors that can be sensed by single-molecule techniques. In this line of research, 1) the intracellular diffusion of MBD3
was explored to monitor active DNA demethylation and 2) the cell cycle-dependent activity of MBD3 was characterized. In these attempts my study establishes the dissociation
of MBD3-DNA as a marking event in active DNA methylation, which might be involved
in early oncogenesis. Moreover, the role of MBD3 in the DNA maintenance methylation
is revealed for the first time – i.e., it constitutes a key balancing force to sustain the DNA
methylation homeostasis.

xxi
Considering its importance in DNA methylation, MBD3 was proposed to participate
in brain cancer because the central nervous system possesses abundant DNA methylation
marks and active methyl metabolism. Hence in the fourth chapter of my dissertation the
regulatory landscape and clinical implication of MBD3 in human malignant glioma is
studied. Utilizing whole-genome transcriptome microarray, the MBD3-mediated epigenetic regulation in glioma was profiled. The data uncover that MBD3 stands in the midst
of an exquisite anti-glioma network via influencing a large number of transmembrane
proteins and nuclear factors. By analyzing the differentially expressed genes upon depletion of MBD3, the MHC class II molecules were identified to be a group of downstream
effectors activated by MBD3, which provides important insight into the anti-glioma immunity. Furthermore, MBD3 functions to impact a wide range of non-coding RNAs including the oncogenic miR-17-92 cluster whose dysfunction could lead to an aggressive
glioma proliferation and metastasis. From a pilot clinical study, the expression level of
MBD3 was found to positively correlate with the patient prognosis and thus could be explored as a novel epigenetic biomarker.
Reactivation of tumor supper genes using DNA demethylating agents has proven to
be effective in treating hematopoietic malignancies, but efficient delivery of these drugs
into solid tumors is a challenging task. In the fifth chapter a polymeric nano-vector comprising PLGA and PEG is developed to improve the solubility, bioavailability, and therapeutic potency of the FDA-approved DNA demethylating agents – AZA and DAC. With
equimolar drug content, the nano-conjugated AZA showed better anti-proliferative effect
than free drug in treating xenografted breast cancer. This formulation can also be used to
deliver a safe dosage of DAC for sensitizing the alkylation-resistant glioblastoma cells to

xxii
temozolomide. Moreover, the improved cell uptake and drug release was characterized
by single-molecule tools. The results demonstrate that PLGA-PEG nano-micelles could
rapidly enrich in cancer cells and resist to efflux. Notably, the pH-dependent hydrolysis
of PLGA enables a targeted drug release in acidic cancer cells featuring overactive glycolysis. Hence, this line of research describes a novel strategy to enhance epigenetic therapy and provides a cost-effective option for future pharmaceutical applications.
The sixth chapter of my dissertation presents a light-controllable technique for locispecific epigenome editing. The optogenetic proteins CRY2-CIB and PHYB-PIF are photosensitive pairs whose associations can be induced by blue and red light, respectively.
Under proper illumination, CRY2 or PHYB is rapidly photoactivated to couple with CIB
or PIF, and their optogenetic associations are reversible in the absence of the triggering
light. The first half of this chapter elucidates the feasibility of using single-molecule fluorescence tools to characterize real-time optogenetic binding kinetics. In the second half, a
pair of DNMT3A-CRY2-mCherry and TRF1-CIB1-EGFP fusion proteins was constructed to achieve selective de novo DNA methylation at subtelomeric CpGs. By varying the
illumination conditions, the subtelomeric methylation can be incrementally manipulated.
These optogenetic modules provide a powerful way to study DNA methylation and can
be conveniently adapted for multiplexing epigenome editing and in vivo applications.

1

CHAPTER 1. INTRODUCTION

1.1

Epigenetics and DNA Methylation

According to the definition by the NIH “Roadmap Epigenomics Project,” “Epignetics is an emerging frontier of science that involves the study of changes in the regulation
of gene activity and expression that are not dependent on gene sequence.” Epigenetic
modifications, through modulating the physicochemical properties of chromatin, dynamically switch on and off the transcription of relevant genes. One of the longest studied epigenetic mechanisms is DNA methylation, i.e., the transfer of a methyl group from Sadenosylmethionine (SAM) to 5-carbon of the pyrimidine ring in cytosine (Figure 1.1).
DNA methylation is intimately involved in life and diseases, and the DNA methylome of
a particular cell or organism can be inherited over generations. Therefore, understanding
of DNA methylation constitutes a cornerstone for modern biology and medicine.

1.1.1

Overview

For a typical human cell, 3 billion base pairs (bp) of DNA are compacted in its nucleus, which however only encode approximately 21,000 genes. This limited repertoire of
genes is shared by numerous differentiated cells and expressed in a precisely controlled
manner during the lifespan of every person. For a long period in history, it has baffled
scientists why monozygotic twins could have distinct personalities and susceptibilities
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to certain diseases even though they boasted the identical genomic information. Genetics
alone is far from sufficient to explain the biological diversity and phenotypic variations
thereto. In 1940s, C.H. Waddington first coined the term “epigenotype” to describe the
causal interactions between the genotype and phenotype during development.1 However,
it was vastly unknown on what mechanism bridged a fixed set of genetic materials to the
developmental divergence among somatic cells in a metazoan organism. First discovered
by T.B. Johnson and R.D. Coghill in 1925,2 the presence of 5-methylcytosine (5mC) was
later proposed to inactivate one X chromosome in female genome and in 1970s 5mC was
established to be a negative regulator for gene expression.3, 4 Since then, DNA methylation and other epigenetic modifications have filled the gap to explain the time- and context-dependent gene expression in a single cell. Over the past decades, researches have
accumulated to reach the conclusion that DNA methylation is indispensable for virtually
all biological processes.
In mammalian cells, the enzymatic reaction of DNA methylation preferably occurs at
a CpG dinucleotide that is not uniformly distributed over the genome. A considerable
portion of CpGs concentrate in short clusters and stretches called CpG islands [CGI, a
500-2,000 bp region having at least 50% of CG content and 60% of an observed-toexpected CpG ratio, i.e., number of CpGs × length of sequence/(number of C × number
of G)] near or within the transcription start site of genes (e.g., promoters). Although 70%80% of scattered CpGs are methylated, most CGIs in promoters are devoid of DNA
methylation to keep the genes poised for activation. Once heavily methylated under a diseased condition, the promoter region would be condensed by a series of repressor factors
and become inaccessible to transcription activators.
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Figure 1.1 Diagram of DNA methylation. A methyl group is transferred from SAM to
cytosine by DNMT enzyme to repress a gene.

In the epigenetic network, DNA methylation is not an isolated modulator but oftentimes connect a wide range of partners to achieve transcriptional inhibition. For instance,
5mC site could recruit methyl-CpG-binding domain protein 2 (MBD2) and its associated
Mi-2/NuRD complex containing histone deacetylases (HDACs) to temporarily turn down
a gene.5 In comparison, 5mC occupied by methyl-CpG-binding protein 2 (MeCP2) would
attract the histone H3 lysine 9 (H3K9) methyltransferase SETDB1 and heterochromatin
protein 1 (HP1).6 In this scenario, DNA methylation acts in cohort with histone modifications and chromatin-remodeling factors to form heterochromatin for a long-term, steady
gene silencing.
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1.1.2

DNA Methylation in Life and Diseases

For a healthy cell where most of its CGIs in promoters are unmethylated, the CpGs
in other regions such as gene bodies and intergenic repetitive elements are heavily methylated to maintain the chromosomal integrity and stability. In the embryogenesis and development of a diploid organism, DNA methylation also plays a crucial role. All human
genes have two alleles with one from the maternal germ cell and the other from the paternal source. Genomic imprinting is an epigenetic process by which some genes are expressed in a parent-of-origin-specific manner. If only the allele from the mother needs to
be transcribed, the other one from the farther has to be imprinted, i.e., silenced by DNA
methylation. Under a similar circumstance, the female somatic cells have two X chromosomes but only one copy is transcriptionally active whereas the other one is often epigenetically inactivated. This X-chromosome inactivation is controlled by an exquisite
mechanism that primarily depends on the DNA methylation mediated heterochromatin
formation. Another critical process involving DNA methylation lies in tissue differentiation and lineage fidelity. For a mature tissue or organ to carry out its normal function, not
all the genes in genome are required. Differentiated from a pluripotent stem cell to a particular cell type, a large number of unneeded genes are switched off by DNA methylation
and this epigenetic memory would be faithfully passed down to keep the lineage identity.
Despite that DNA methylation at the gene promoter directly suppress that gene, intragenic DNA methylation is also able to fine-tune the activity of RNA polymerase and the alternative splicing of mRNAs.7, 8
Due to its functional versatility and importance, DNA methylation is implicated in a
myriad of pathological conditions. Mistakes in genomic imprinting have pleiotropic con-

5
sequences such as placental deficiencies, fetal undergrowth or overgrowth, increased risk
of childhood cancers, neurological defects and developmental retardation. The Angelman
(AS) and Prader-Willi (PWS) syndromes are two distinct, reciprocally imprinted disorders that share the same chromosomal location. Loss or inactivation of at least one
15q11-13 gene occurs in AS and PWS, with maternal deficiencies giving rise to AS and
paternal defects causing PWS. Thus for the genes involved in AS and PWS, both of their
alleles are not functional because one is silenced by imprinting and the other one is mutated. Other common imprinting disorders include: Beckwith-Wiedemann syndrome
(11p15), Russell-Silver syndrome (11p15), Albright’s hereditary osteodystrophy (20q13),
and NOEY2 dysfunction (1p31).9
Recently, in a plethora of studies aberrant DNA methylation has been defined as a
driving force for oncogenesis. The best-characterized epigenetic events in relation to cancer are: 1) global DNA hypomethylation and 2) intense hypermethylation at the promoters of certain tumor suppressor genes.10 The epigenome of a cancer cell could be depleted
by 20%-60% of its DNA methylation, mostly at coding regions, enhancers, introns, and
repetitive sequences. In the cancerous DNA demethylation, one destructive effect arises
via activation of the endogenous retrovirus and transposable elements present in mammalian genomes, which in turn potently compromise the expression of growth regulatory
genes, foster genome-wide mutations, and enforce fatal chromosomal recombinations. De
novo methylation at the promoter region of tumor suppressor genes is another critical step
facilitating cancer initiation. Although the majority of promoters CGIs are free of DNA
methylation, an anomalous gain-of-methylation for a key tumor suppressor gene could
unduly release the precancerous cells from the restrictions on proliferation, metabolism,
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adherence, and metastasis. Notably, the pattern of promoter hypermethylation in some
genes is highly tissue-specific and thus can be explored as novel biomarkers. For example,
upon DNA hypermethylation, the deregulation of BRCA1 is a hallmark of breast and
ovarian tumors, and the repression of hMLH1 predominantly occurs in endometrial, colorectal, and gastric neoplasm.11 In contrast, hypermethylation of the MGMT gene can
bring about a prognostic benefit for glioma patients who receive the standard alkylating
chemotherapy (e.g., temozolomide) because inactivation of MGMT alleviates the intrinsic activity of reversing the therapeutic guanine alkylation.

1.1.3

DNA Methylation-Related Enzymes

Conserved along cell division, modified during cell differentiation, and transgressed
in cell transformation, the patterns of genome-wide DNA methylation actively dictate cell
fate and are under a rigorous control by methyltransferases and demethylases. Thus the
DNA methylation homeostasis is stringent on a delicate balance between these two forces
of enzymes and their co-factors.
The addition of a methyl mark to cytosine is mainly catalyzed by DNA methyltransferases (DNMTs) in human cells, and to date three genuine DNMTs have been biochemically characterized with the exception that DNMT2 was later found to be a RNA methyltransferase.12 The catalytic domain of DNMTs is highly conserved, featuring a ~400 amino acids sequence containing motifs I-X in the C-terminus.13 The N-terminal regulatory
domain distinguishes DNMT1 from DNMT3A/B: a proliferating cell nuclear antigen
(PCNA)-binding domain (PBD), a pericentric heterochromatin-targeting sequence (TS), a
CXXC zinc finger motif, and two bromo adjacent homology (BAH) domains are con-
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tained in DNMT1; in comparison, the N-terminal domain of DNMT3A and DNMT3B is
composed of a conserved Pro-Trp-Trp-Pro PWWP domain and a plant homeodomain
(PHD, also known as ADD, i.e., ATRX-DNMT3-DNMT3L) in their N-terminus (Figure
1.2A). DNMT1 was discovered in 1988 and DNMT3A/B were discovered ten years later.14, 15 In the early years, based on their binding preference for hemi-methylated or unmethylated DNA, these DNMTs were arbitrarily categorized as maintenance methyltransferase (DNMT1) and de novo methyltransferase (DNMT3). DNMT1 is the most abundant
DNMT throughout the life cycle of a differentiated cell whereas DNMT3 largely enriches
in early development. DNMT1 starts to peak its expression in S-phase and possesses a
substrate preference for hemi-methylated DNA at replication loci.16 During the establishment of tissue-specific methylomes from an epigenetically naive stem cell, DNMT3A
and DNMT3B are responsible for adding numerous de novo methylation marks to those
imprinted genes, satellite sequences, long and short interspersed nuclear elements
(LINEs/SINEs), and heterochromatin.17 However, in recent years studies have shown that
actually DNMT1 and DNMT3 are not mutually independent but act in concert for the
methylation homeostasis.18 DNMT3 can support DNMT1 in the maintenance methylation
of repetitive elements while overexpression of DNMT1 would result in a marked gain of
de novo methylation.19, 20
In the production of germ cells, the DNA methylation landscape in the gametes, especially the paternal copy, undergoes a rapid and massive demethylation. However, the
first active DNA demethylase in human was not found until 2009.21 Before that, the conventional view in the removal of DNA methylation inclined to: 1) DNA demethylation
needs to be achieved via a passive dilution (i.e., the hemi-methylated sites are stopped to
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become fully methylated after DNA replication) or 2) the methylated cytosine should experience deamination to become thymine and then be replaced by a new cytosine through
the base excision repair (BER), yet both of which were deemed as utterly inefficient processes. Since the recent discovery of the ten-eleven-translocation (TET) family proteincatalyzed conversion of 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine
(5fC), and 5-carboxylcytosine (5caC), the full picture of DNA demethylation has come to
our sight: the oxidation of 5mC essentially facilitates the passive and active demethylation processes. The existence of 5hmC at hemi-methylated sites (i.e., 5’-5mC-G-3’:3’-G5hmC-5’ pairs) can remarkably accelerate the passive demethylation while 5fC and 5caC
are better substrates to be processed by thymine DNA glycosylase (TDG) in BER.22 TET
family proteins (TET1-3) are a group of Fe(II)/α-ketoglutarate (α-KG)-dependent oxygenases and harbor a double-stranded β-helix (DBSH) core motif where high-valet Fe(IV)
is generated to oxidize the methyl group on cytosine. TET1 and TET3 also contain a
CXXC domain in their N-terminus to facilitate binding with CG-rich sequences (Figure
1.2B). TET3 is predominantly enriched in zygotes and responsible for the active demethylation of the paternal epigenome while TET1 and TET2 are more expressed in primordial germ cells. In some tissues (e.g., brain, heart, lung, liver, and kidney) TET proteins are
intrinsically expressed, exerting critical influences on the fidelity of differentiation.23, 24
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Figure 1.2 Schematic illustration of human methyltransferases and demethylases.

Aberrant expression or mutations of DNMTs and TETs are extensively implicated in
various diseases, particularly in hematopoietic malignancies. The pathological translocation of mixed lineage leukemia protein (MLL)-TET1 [t(10;11)(q22;q23)] is a common
event in acute myeloid leukemia (AML).25 TET2 is frequently mutated in lymphoma,
myelodysplastic syndrome (MDS), myelofibrosis, and different types of leukemia.24 Mutations in DNMT3A are usually correlated with poor prognosis for patients having AML
or MDS.26, 27 The biallelic DNMT3B mutation is the main cause for the rare “immunodeficiency, centromeric region instability, and facial anomalies syndrome” (ICF).28 In addition, abnormal DNA methylation induced by dysfunctional DNMTs or TETs could substantially promote solid tumor initiation and progression.
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1.1.4

DNA Methylation-Binding Proteins

Besides the methylation-editing enzymes, methylated cytosine can also be recognized by a group of reader proteins including Kaiso family proteins, MBD family proteins, and the SET- and Ring finger-associated (SRA) domain proteins (Figure 1.3).
These proteins either function as a structural component of chromatin or serve as a coordinator to connect other factors. Kaiso and Kaiso-like proteins interact with DNA methylation through three Kruppel-like C2H2 zinc finger motifs but they require two consecutive mCpGs for an efficient binding.29, 30 In cooperation with HDACs and chromatinremodeling factors, Kaiso turns out to be a strong transcription repressor. The first MBD
protein MeCP2 was discovered in 1992,31 followed by the discovery of the other MBD
members in the next several years. Till today at least ten MBD-containing proteins have
been identified in human being. The core DNA-binding motif of MBD proteins contains
about 70 residues folding into an α/β sandwich structure that is embedded into the major
groove of target DNA sites.32 The binding specificity and affinity between MBD and
DNA methylation is subjected to changes of some key residues such as Val-20, Arg-22,
Lys-30, Tyr-34, Arg-44, and Ser-45.32-34 For instance, the human MBD2 and MBD3 are
highly homologous, but MBD3 has a much weaker in vitro binding affinity with 5mC
owing to the K30H and Y34F substitution.35 Over the past years the SRA domaincontaining protein UHRF1 (also known as NP95 or ICBP90) has drawn considerable attention since the finding that UHRF1 could co-localize with hemi-methylated DNA and
DNMT1 during the S-phase in cell cycle.36-38 After locating a hemi-methylated CpG site,
UHRF1 would quickly move in and flip the methylated cytosine out of the double helix, a
characteristic conformation subsequently recruiting DNMT1 to transfer a methyl group to
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the unmethylated CpG on the complementary strand. This discovery reveals that UHRF1
is a vital part in the DNA maintenance methylation.

Figure 1.3 Solved structures of major DNA methylation-binding proteins. This figure was
generated using PyMOL with structural information retrieved from the RCSB PDB database: Kaiso (PDB ID: 4F6N), MBD (PDB ID: 2YK8), SRA (PDB ID: 2ZO1).

As mentioned above, DNA methylation-binding proteins have evolved to gain a diversity of functions to interpret the epigenetic code on DNA. To effectively regulate a
gene, DNA methylation often needs to co-work with other epigenetic modulators. For
instance, a number of DNA methylation-binding proteins (e.g., Kaiso, MeCP2, MBD2,
MBD3, and SRA) directly or indirectly associate with HDACs; MBD1 usually co-exists
with H3K9 trimethylation and HP1; and both MBD2 and MBD3 are core subunits of the
nucleosomal remodeling deacetylase complex Mi-2/NuRD.39 Interestingly, under certain
circumstances some MBD proteins (e.g., MBD2, MBD3, and MBD4) can interact with
unmethylated DNA or even demethylate their binding sequences.40-42 In this regard, these
proteins might also be involved in gene activation.
A multitude of diseases and disorders are linked to DNA methylation-binding proteins. The best-known one is Rett syndrome, a neurodevelopment disorder caused by mu-
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tations in MeCP2.43 MBD3 is important for development and deletion of MBD3 in mouse
model is embryonic lethal.44 Except for MBD2, mutations in all other MBD proteins have
been identified in autism spectrum disorder.39 In cancers, abnormal expression of one or
more MBD proteins has been frequently observed, such as overexpression of MeCP2 and
MBD2 in breast cancer,45 overexpression of MBD2 and MBD4 in brain glioblastoma,46,
47

up-regulation of MBD1 and down-regulation of MBD2 in prostate cancer,48 and down-

regulation of MBD3 in gastrointestinal and endometrial cancers.49, 50

1.2

Nanoscale Detection and Manipulation of DNA Methylation

At present our understanding of epigenetic regulation has primarily come from ensemble, static, and end-point tests utilizing a population of cells or bulky samples, largely
overlooking the cellular heterogeneity and real-time intermediates. In order to dissect and
engineer a single cell, achieving a finer experimental scale than that in the conventional
biological approaches is imperative. Advanced single-molecule fluorescence techniques
open a unique window for us to inspect epigenetic molecules and events with marvelous
resolutions. In the meantime, nanobiotechnology provides us tremendous opportunities to
edit epigenome with unprecedented convenience and accuracy.

1.2.1

Overview

In eukaryotic cells, the basic unit for epigenetic regulation is nucleosome that contains a histone octamer core wrapped by 147 bp of DNA (Figure 1.4). Epigenetic modifications function through influencing the intertwined DNA-histone interface to control
gene transcription. However, the extremely small size of a single nucleosome – approxi-
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mately 11 nm – poses a daunting task to detect or manipulate a specific type of epigenetic
mark on it.

Figure 1.4 Basic unit for epigenetic modifications to occur – a single nucleosome.

Capturing and controlling epigenetic events in single living cells require the spatial
and temporal resolution of the methodology to meet the scales of the ongoing cellular and
molecular activities (Figure 1.5). Yet the intracellular environment is extremely crowded.
Given a human cell with an average volume of ~1 picoliter, 3 × 109 bp DNA (equivalent
to 2 meters if fully stretched) is packed in its nucleus whose diameter is merely 10-15 microns. Even DNA methylation only constitutes ~1% of the human genome, which could
generate a fairly high in situ density of 5mC at particular regions such as satellite DNA
repeats and heterochromatin sites. To overcome the bottleneck of microscopic observation, nanoscale imaging and molecular engineering are becoming increasingly important.
On a different note, the genome-wide content of DNA methylation is dynamically fluctu-
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ating along with different cell behaviors, posing another layer of complexity for singlecell studies.

Figure 1.5 Spatiotemporal scales required for single-cell and single-molecule studies.

1.2.2

Single-Molecule Fluorescence Techniques

About 340 years have passed since Robert Hooke and Antonie van Leeuwenhoek
popularized the modern microscopy. The 20th century has embraced an exciting number
of breakthroughs that rendered optical microscope an irreplaceable part in life science
research. The invention of fluorescence microscope in 1910s has spurred a revolutionary
leap, after which fluorescent labeling has quickly become the norm for observing micro-
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organisms and subcellular structures. Derived from the principle of fluorescence, the further developments of confocal microscopy (1960s), fluorescence fluctuation microscopy
(1970s), total internal reflection fluorescence microscopy (1980s), multi-photon microscopy (1990s), light-sheet fluorescence microscopy (1990s), and super-resolution microscopy (2000s) have been enormously advancing the spatiotemporal limits of optical dissection. The capability of single-molecule fluorescence techniques to provide in situ, real-time information of intracellular dynamics is an unparalleled advantage. In this thesis,
a toolset of ultrafast pulsed lasers and single-photon avalanche diode (SPAD) detectors
are integrated into a scanning confocal time-resolved microscope system (PicoQuant) for
probing the DNA methylation-related activities. The mainly used techniques are depicted
in Figure 1.6 and introduced below.
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Figure 1.6 Function modules in a single-molecule fluorescence platform. The system is
based on an inverted confocal scanning microscope. Ultrafast pulsed lasers and SPAD
detectors are implemented to realize time-correlated single-photon counting. In the confocal detection volume, the recorded fluorescence fluctuation can be used for FCS and
PCH, and the photon decay pattern can be interpreted in FLIM.

Fluorescence correlation spectroscopy (FCS). First developed by Douglas Madge, Elliot
Elson, and W.W. Webb in 1972, FCS takes use of the spontaneous fluorescence fluctuation (at a microsecond resolution) due to the molecular diffusion in-and-out a femtoliterlevel volume to biophysically infer the concentration, diffusion rate, hydrodynamic size,
and interaction kinetics of the fluorescent targets.51, 52 In FCS analysis, an autocorrelation
function is extracted from the fluorescence fluctuation trace which describes the similarity between two signal events as a function of the time lag (τ):
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G(τ ) =

δ F (t ) ⋅ δ F (t + τ )
F (t )

2

where F is the average fluorescence intensity over time (t), and δ F (t ) = F (t ) − F (t ) .
For 3D free diffusion, the autocorrelation function can be correlated to single-molecule
properties using:
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where N is the average number of molecules, f i is the fraction of species i, κ is the
spatial dimension of the detection volume (the ratio of radial w0 to axial z0 radii), and

τ Di is the characteristic diffusion time (the average time for one molecule dwelling in the
detection volume). The concentration of molecules can be calculated as: C = N / Veff ,
where Veff is the effective detection volume: Veff = π 3/2 w02 z0 . From τ D the diffusion coefficient (D) of molecules can be calculated as: D = w02 / 4τ D . The hydrodynamic size (R)
of molecules can also be determined from the Stokes-Einstein equation: D =

kT
6πη R

,

where k is the Boltzmann’s constant and η is the environmental viscosity. For a constrained diffusion condition such as 2D diffusion and anomalous restricted diffusion, different fitting models should be opted accordingly.
Photon counting histogram (PCH). The sensitivity of FCS to distinguish different molecules heavily relies on molecular size, which requires a minimum of 1.6-fold change in
hydrodynamic size or 4.1-fold change in molecular weight to separate two species.53 The
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invention of PCH method greatly enriches the single-molecule toolbox with another fluorescent characteristic – molecular brightness (ε), which is especially useful to reflect the
stoichiometry of fluorophores having oligomeric status.54,

55

Collected as the average

number of photons emitted from per molecule per sampling time, single-molecule brightness is physically defined by:

ε = I 0N βη wT
where T is the integration time increment, ηw is the detection efficiency, I0 is the maximum excitation at the center of detection volume, N is 1 for single-photon system, β is
the excitation probability. The weight averaged ε is independent of the ensemble concentration and can be mathematically determined from the fluctuation trace by:

ε =

σ2 − I
= ∑ f iε i
γ I
i

where εi is the brightness of species i, fi is its fractional intensity, and σ2 is the detection
variance. The gamma factor (γ) is an excitation-dependent value and is 0.3536 for singlephoton confocal system.
Fluorescence lifetime imaging microscopy (FLIM). Fluorescence lifetime (τ, a different
parameter from the time lag in autocorrelation function) is defined as the average time
one fluorochrome stays at the excited state before returning to the ground state by emitting photons, which can be illustrated as:

τ=

Γ
Γ + knr

where Γ is the emission rate and knr the non-radiative decay rate, both of which are subjected to physicochemical influences. Fluorescence lifetime is independent of molecule
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concentration and excitation intensity so that can be used a robust measure to sense conformational changes, associations, and environmental factors. In the time-domain FLIM,
fluorescence lifetime is derived from the time-correlated single-photon counting (TCSPC)
histogram that records the arrival time of photons under pulsed excitation (Figure 1.7).

Figure 1.7 Schematic of time-domain fluorescence lifetime measurement. After a pulsed
excitation, the arrival time of each collected photon is compiled to a TCSPC histogram.
Fluorescence lifetime herein is determined as the decay time for the highest F0 to become
F0/e.
Förster resonance energy transfer (FRET). Discovered by Theodor Förster in 1946,
FRET is a physical process of non-radiative energy transfer between two fluorochromes
with proper spectral overlap and dipole-dipole orientation (Figure 1.8). The FRET efficiency (E) greatly depends on the distance (r) between the donor and acceptor with an
inverse 6th power law:

E=

1
1 + ( r / R0 )

6

20
FRET mainly manifests within an inter-dipole distance of 1-6 nm and therefore can
serve as a biophysical “ruler” to scrutinize molecular interactions. When acceptor molecules are nearby, a reduction in the fluorescence lifetime of donor molecules indicates the
occurrence of FRET and is quantitatively related to the FRET efficiency:
E = 1−

τ DA
τD

where τ DA and τ D are the fluorescence lifetimes of donor in the presence and absence of
acceptor, respectively.

Figure 1.8 FRET and FLIM-FRET. Non-radiative energy transfer would occur when the
donor and acceptor are closer than 10 nm. The FRET efficiency depends on the distance
between the dipole moments of fluorophores. FRET leads to a reduction in the fluorescence lifetime of donor and can be visualized in FLIM images.

1.2.3

Epigenetic Therapy

Epigenetic pathology has the potential to reshape cellular functions and appreciably
foster an oncogenic transformation. As mentioned above, epigenetic silencing of tumor
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suppressor genes is one of the driving events in cancer progression and drug resistance.
Fortunately, epigenetic errors in cancer, unlike genetic aberrations, can be reversed by
proper agents with relative ease and less side effects because epigenetic modifications do
not alter the DNA sequence.56, 57 This property makes epigenetic therapy a promising intervention strategy. DNA methylation and histone deacetylation are the two major mechanisms to compress chromatin and inhibit gene expression. Therefore inhibitors targeting
DNMTs and HDACs have been designed and synthesized as a new line of chemotherapy.
So far, five epigenetic drugs have been approved by US Food and Drug Administration
(FDA): 5-azacytidine (AZA, 2004) and 5-aza-2’-deoxycytidine (DAC, 2006) for treating
MDS; vorinostat (2006) and romidepsin (2009) for treating cutaneous T cell lymphoma;
and panobinostat (2015) for treating multiple myeloma, while more compounds are under
clinical trials or preclinical investigations.57, 58
AZA and DAC are cytidine analogues with their 5-carbon replaced by a nitrogen atom so that cannot be methylated by DNMTs anymore. Upon uptake by cells, these cytidine analogues are triphosphorylated and integrated into newly synthesized DNA strands
during the S-phase. After several rounds of cell division, the covalent entrapping and
subsequent degradation of DNMT1 at the drug incorporation sites would significantly
deplete the endogenous methylation reservoir, which achieves a therapeutic effect by reactivating a group of tumor suppressor genes such as p16, RB, PTEN, and hMLH1.58-61
As an alternative, a handful of non-nucleoside molecules are developed to directly target
the catalytic domain of DNMTs or HDACs by which the deregulated genes can be restored.62, 63
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Besides being applied separately, epigenetic therapies are more often used in combination with other chemo-drugs to achieve a prognostic improvement. To name a few,
AZA could potently sensitize prostate cancer to decetaxel and cisplatin;64 vorinostat and
paclitaxel together elicit a much stronger anti-ovarian cancer activity;65 both DNMT and
HDAC inhibitors are effective in sensitizing the tamoxifen-resistant breast cancer to
hormone therapies.66, 67 Another strategy is to look for synergistic effects from combining
DNMT and HDAC inhibitors and utilizing their reciprocal modulation on gene activation.68, 69 One thing worth mentioning, when employing epigenetic treatments, is that they
would not only reactivate tumor suppressor genes but also boost the expression of cancerspecific antigens. It thus holds another promise for the incorporation of epigenetic sensitization to the current booming immunotherapy.70

1.2.4

Epigenome Editing

In order to fully understand the functional implication of an epigenetic mark, the capability of artificially adding or removing such modification in living organisms is an
emerging challenge. From another perspective, searching for tools that can epigenetically
regulate genetic activity without altering the coding sequence is becoming a pressing demand for biotechnology. Hence, epigenome editing has been quickly arising as a hot topic in basic research and engineering regime. The first generation of epigenome editing
derived from conventional techniques such as small interfering RNA (siRNA) or targeted
mutation to systematically disable an epigenetic enzyme, then depleting a relevant modification and its regulatory impact. In this way, the majority of epigenetic enzymes and
factors have been characterized regarding their influences on epigenome and phenotypic
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traits in a variety of model organisms. However, strategic knockout or overexpression of
an epigenetic protein at the global level cannot adequately address the query on epigenetic control over a specific gene of interest and sometimes would even give rise to severe
side effects since some epigenetic molecules are indispensable for survival. The past decade has witnessed the soaring popularity of genome engineering enabled by the discovery
of novel DNA-targeting modules, including zinc finger nucleases (ZFNs),71 transcription
activator-like effector nuclease (TALENs),72 and clustered regulatory interspaced short
palindromic repeats and its associated bacteria endonuclease 9 (CRISPR/Cas9).73 With
continuing improvements on and implementation of these programmable DNA sequencerecognition proteins, the next generation of loci-specific epigenome editing has been devised.
Rather than by introducing DNA breaks, loci-specific epigenome editing is realized
by replacing the nuclease component in ZFNs, TALENs, or CRISPR/Cas9 with an epigenetic effector to confer the desired modification onto the targeted sequence (e.g., connecting a deactivated CRISPR/Cas9 to a favorable epigenetic enzyme74, 75) (Figure 1.9). In
design, an epigenome editing module should comprise two functional domains: a targeting domain and an effector domain, between which a linker sequence can be inserted according to the covering length.76 The targeting specificity and effectiveness can be evaluated with affinity-based assays such as MeDIP. The prominent advantages for epigenome
editing over genome editing include: first, the outcome from epigenome editing is more
predictable whereas the homologues recombination and non-homologous end-joining induced by genome-editing nucleases may lead to entirely different phenotypes; second, the
extent of gene expression by epigenome editing can be fine-tuned in contrast to a dichot-
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omous on/off effect by genome editing. Substantive attempts have been invested and they
successfully laid the foundation on how to harness these powerful tools. For example, by
fusing a TET catalytic domain with a zinc finger or TALE proteins, the target gene could
be rapidly demethylated for reactivation.77, 78 Moreover, epigenome editing can be used
to investigate the epigenetic code on histone considering that a same type of modification
yet at different residuals might cause dissimilar outcomes. To this end, it has been found
that demethylating H3K4 or methylating H3K9 could both achieve gene suppression.79, 80
More recently, upon separating the targeting and effector domains and fusing them with a
pair of light-sensitive proteins repectively, loci-specific histone modifications could be
manipulated on demand by remote illumination.81 Thanks to the striving efforts for tool
optimization, precision epigenome editing is striding into a new era and being adapted for
in vivo applications.82
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Figure 1.9 Next generation of epigenome-editing tools combining DNA-targeting modules and epigenetic effectors. (figure adapted from reference [75])
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CHAPTER 2. UTILIZING REAL-TIME DYNAMICS OF MBD3 TO SENSE ACTIVE
DNA DEMETHYLATION

2.1

Introduction

Global DNA hypomethylation, i.e., a genome-wide reduction in 5mC, is one of the
most characterized epigenetic anomalies in cancer. However, it is immensely unclear on
the triggering mechanisms for such an extensive DNA demethylation, which has become
a stumbling block to our in-depth understanding of oncogenesis. Recently, a growing
body of evidence has noted that loss of 5hmC also manifested in a number of cancers.83,
84

In the paradigm of active DNA demethylation, 5mC is depleted through a series of ox-

idization to 5hmC, 5fC, and 5caC.85 The concurrent decrease of 5mC and 5hmC in tumor
cells indicates that the cancerous DNA hypomethylation might be markedly attributed to
an active process involving TET enzymes.10, 22
Hypoxia is the typical microenvironment for solid tumors featuring excessive cell
growth. As demonstrated before, low oxygen tension is critical for the maintenance of
malignant tumorigenic cells (or cancer stem cells) that are responsible for a fatal tumor
progression and metastasis.86 This hypothesis was indirectly supported by a study showing that culturing human fibroblasts under hypoxia could more efficiently reprogram the
cells to induced pluripotent stem cells.87 Complementary to the finding that cancer stem
cells possess a much lower DNA methylation compared to physiologically differentiated
cells, another line of research has revealed that hypoxic stress could evoke a substantial
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DNA demethylation in cancer cells and tissues.88, 89 These reports collectively suggest
that hypoxia may be closely related to active DNA demethylation in tumorigenesis. To
fully establish this connection, a cost-effective method for rapid quantification of all cytosine modifications in trace amount of DNA is needed. Although techniques including
liquid chromatography-mass spectrometry (LC-MS) and high-throughput next-generation
DNA sequencing provide unparalleled power for epigenetic research, they are laborious,
time-consuming, and not ideal for multiplex detection.90 In this regard, an enhanced enzyme-linked immunosorbent assay (ELISA) is first developed to validate the hypoxiainduced active DNA demethylation in HeLa cells.
Furthermore, limited tools exist to capture the ongoing DNA demethylation in single
cells. In the following work, with single-molecule FCS the process of active DNA demethylation is successfully captured by monitoring the real-time dynamics of MBD3 protein in living HeLa cells exposed to hypoxia. Among the MBD family members, MBD3
possesses the lowest binding affinity with DNA methylation site due to the residual mutations in its DNA-binding motif (Figure 2.1), which property makes MBD3 a candidate
molecule to be detached from chromatin when the occupied CpG site is undergoing an
enzymatic conversion. For active DNA demethylation to proceed, the already existing
5mC and 5hmC need to be enzymatically converted to 5fC or 5caC (suitable substrates
for TDG-mediated BER). As a binding protein for both 5mC and 5hmC, MBD3 is expected to promptly dissociate from DNA in order to expose the modified cytosine; otherwise its steric hindrance would impede the action of TET and TDG proteins. Hence,
timely detection of the subtle changes in the MBD3 diffusion – the transition from bound
to unbound state – provides an elegant solution to sense the process of active DNA de-
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methylation. FCS is a single-molecule approach that can conveniently quantify protein
diffusion with resolution down to microseconds. With this temporal sensitivity, the accelerating MBD3 diffusion in the cell nucleus is proposed to be a precursory event for active
DNA demethylation.

Figure 2.1 Comparison of the core DNA-binding motifs in the major MBD proteins. The
five key residues for substrate recognition are highlighted in light blue. The K30H/Y34F
substitutions in MBD3 are highlighted in dark grey. The structural alignment for MBD2
(PDB ID: 2KY8) and MBD3 (PDB ID: 2MB7) is generated with PyMOL.

2.2
2.2.1

Methods and Materials

Cell Culture, Plasmid Transfection, and Hypoxia Induction

HeLa cells were routinely cultured in DMEM/F-12 medium supplemented with 10%
fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin in a 37°C humid-
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ified incubator supplying 5% CO2. The pGFP-MBD3 plasmid was a kind gift from the Dr.
Adrian Bird’s group (University of Edinburgh, UK) and transfection was conducted with
Lipofectamine LTX & Plus reagents (Life Technology). Before transfection, 5 × 104 cells
were seeded onto a sterilized No.1 coverslip (VWR International) placed in 12-well plate
with 2 mL fresh culture medium. After the cells reached 70-80% confluence the medium
was replaced with antibiotics-free, low-serum medium for another 24 h culture. Then 100
ng plasmid DNA, 2.5 µL LTX reagent, and 0.1 µL Plus reagent were dissolved in 200 µL
Opti-MEM medium and incubated for 10 min before adding to the culture well. Transfection lasted for 24 h before hypoxia induction. Since FCS measurement requires an optimal concentration ranging from hundreds of pM to nM, the cells selected for data collection have an average concentration of 80-120 nM MBD3-GFP expressed in their nuclei.
Acute hypoxia was induced with 1 mM sodium dithionite (Na2S2O4, Sigma) to fast
deplete dissolved oxygen in culture medium, which could efficiently lower the pO2 to 10
Torr whereas 100% N2 could only lower the pO2 to 30-60 Torr.91, 92 The pH of medium
was re-adjusted to 7.4 by HEPES to buffer the acidification potential of Na2S2O4. To
maintain the hypoxic condition, medium containing Na2S2O4 was changed every 8 h.

2.2.2

Enhanced ELISA for Quantification of DNA Methylation Marks

On the basis of conventional ELISA that takes use of primary and secondary antibodies, a third layer of signal amplification is designed for an enhanced ELISA by conjugating secondary antibody with biotin. When antigen is present, streptavidin coupled to
multiple horseradish peroxidase (HRP) molecules would be specifically enriched (Figure
2.2). For a 96-well assay plate, a maximum of 200 ng DNA could be input for analysis,
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from which 5fC and 5caC are hard to be detected (less than 0.01% in genomic DNA).
With this optimized ELISA, all the four types of cytosine modifications can be simultaneously quantified in the same plate.

Figure 2.2 Schematic of the enhanced ELISA utilizing the biotin-avidin coupling.

2.2.3

Biotinylation of Secondary Antibody

Secondary antibodies in PBS were labeled with 50-fold molar excess of succinimidyl-6-[biotinamido]-6-hexanamidohexanoate (NHS-LC-LC-biotin, Pierce) dissolved
in DMSO. The reaction was performed in 10 mM phosphate buffer with 150 mM NaCl
(pH = 7.4) at room temperature for 1 h and the biotinylated antibody was purified by dialysis and size exclusion chromatography with Sephadex G-15 gel column (gel volume:
10 mL). The product was then concentrated and stored at 4°C until use.

2.2.4

Conjugation of Streptavidin with HRP

Streptavidin (Prozyme) and HRP were respectively coupled with succinimidyl 6(3[2-pyridyldithio] propionamido) hexanoate (LC-SPDP, Pierce) and succinimidyl-4-(N-

31
maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate) (LC-SMCC, Pierce) – both
in the molar ratio 1:50 – at room temperature for 1 h. The LC-SPDP was treated with dithiothreitol (DTT, 10 mM) for activation at room temperature for 30 min. The thiolated
streptavidin and maleimide-activated HRP (molar ratio 1:5) were purified with Sephadex
G-15 gel filtration (pre-equilibrated in 5 mM EDTA) and then immediately mixed. The
conjugation was carried out with gentle shaking at room temperature for 2 h. This protein
product was stored at 4°C until use.

2.2.5

DNA Extraction and ELISA Quantification

DNA from HeLa cells was extracted with DNeasy Kit (Qiagen). Purified DNA in
100 µL TE buffer (50 ng for 5mC, 200 ng for 5hmC, 5fC, and 5caC) was added to each
polystyrene plate microwell followed by mixing with 100 µL DNA coating solution
(Pierce) at room temperature for 2 h with gentle agitation. The substrate DNA was then
washed three times with 300 µL of DI water in the microwell. To block residual surfaces,
the microwell was treated with 0.5% (w/v) casein dissolved in PBS (200 µL) at 37°C for
1 h. Primary antibodies used in this study include: mouse anti-5mC-IgG (Eurogentec),
rabbit anti-5hmC/5fC/5caC-IgG (Active Motif). An amount of 0.5 µg/mL of primary antibody diluted in PBS containing 0.5% casein (100 µL) was added and then 1 µg/mL of
biotinylated secondary antibody (100 µL) was reacted with the primary antibody. To
form avidin-biotin complex, 0.5 µg/mL of streptavidin-HRP conjugate (100 µL) was finally added into the microwell. For signal generation, 200 µL colorimetric substrate mixture [50 mM sodium acetate buffer (pH = 5.1) : 1% (w/v) TMB : 3% (v/v) H2O2 = 1,000 :
10 : 1 as volume ratio] was applied for 15 min at room temperature followed by 50 µL of
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2 M sulfuric acid to stop the reaction. The optical intensity was measured by a VersamaxTM absorbance microplate reader (Molecular Device). As shown in Figure 2.3, the
limit-of-detection (LOD) of enhanced ELISA is at least ten-fold lower than that of conventional ELISA when using a standard DNA with 16% of the sequence as 5caC. Approximately 2 pg standard DNA (equivalent to 0.0016% 5caC in 200 ng genomic DNA)
can be detected with enhanced ELISA whereas 20 pg standard DNA cannot generate a
readable signal by conventional ELISA.

----- Enhanced ELISA
----- Conventional ELISA
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Figure 2.3 Comparison of signal amplification between the conventional and enhanced
ELISA for detection of 5caC-containing standard DNA.

2.2.6

Instrumentation for FCS

FCS was performed by using a scanning confocal time-resolved microscope (Microtime, PicoQuant). A 465 nm picosecond pulsed laser was used to excite the GFP tag. The
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power output of excitation was precisely controlled at the µW level by a Sepia PDL 808
driver to prevent phototoxicity. The laser beam was delivered to the sample stage through
an apochromatic water immersion objective lens (60×, NA 1.2, Olympus) and the emitted
fluorescence was collected by the same objective lens, after which the scattered excitation light was cleaned by a dual-band dichroic (z467/638rpc, Chroma). A 50 um pinhole
was employed to block the off-focus photons and the emission signal was finally separated by a band-pass filter (500-540 nm, Chroma) before reaching a SPAD detector (SPCMAQR-14, PerkinElmer). Information of each collected photon was stored in a time-tagged
time-resolved (TTTR) mode (TimeHarp, PicoQuant) in which a time stamp was assigned
to record the photon arrival time after the laser pulse.

2.2.7

Data Analysis for FCS

For live-cell FCS measuring nuclear proteins, two biophysical models are often applied to fit the autocorrelation function and characterize the molecular diffusion. The first
one is anomalous diffusion model:
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where α is the correcting factor to offset the diffusion hindrance caused by the crowded
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where y is the fraction of bound molecules. In experiments of probing MBD3-GFP, both
models were considered and tested as necessary to minimize the fitting residual (χ2) in
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least-square regression algorithm. When fitting with two-component 3D diffusion model,
a reference value for τ Dfree was predetermined from the cytoplasmic MBD3-GFP.
In parallel, the raw autocorrelation data were also analyzed by the maximum entropy
method for FCS (MEMFCS) to validate the robustness of FCS measurement. MEMFCS
is a multi-component model to simultaneously minimize χ2 and maximize entropy S
without a fitting priori.93 The MEMFCS output thus is a continuous distribution of τ D
instead of a presumed number of diffusing components (Figure 2.4). The G(τ) function in
MEMFCS is expressed as:
−1
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1 τ 
G (τ ) = ∫ ai  1 +   1 + 2 × 
 τD   κ τD 
n

where S = ∑ pi ln pi , pi =
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. MEMFCS is particularly useful because of its capability to
∑ ai

unbiasedly reflect the overall status of molecular diffusion in a complex biological system.

Figure 2.4 Processing FCS data by the standard two-component fitting and MEMFCS.
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2.3
2.3.1

Results

Active DNA Demethylation under Hypoxia

To verify the type of DNA demethylation under acute hypoxia, all the four cytosine
derivatives (i.e., 5mC, 5hmC, 5fC, and 5caC) were quantified by enhanced ELISA (Figure 2.5A). In 8 hours a global reduction of all modifications was noted, indicating the occurrence of active DNA demethylation. From the decreasing patterns of 5fC and 5caC,
two peak periods of active DNA demethylation were suggested: the first and the last 8
hours intermediated by a plateau period. During the peak periods, the active demethylation pathway is in full action because 5fC and 5caC are massively depleted by the TDG
enzyme (Figure 2.5B). Considering the heterogeneous cellular responses to the hypoxic
stress, these two demethylation periods might be attributed to distinct cell populations,
i.e., hypoxia-sensitive and hypoxia-insensitive cells, in which the demethylation rates are
not synchronous. The 8-16 h plateau period representing a flat change in the levels of
5hmC/5fC/5caC implies a transition, regarding the contribution to the global hypomethylation, from hypoxia-sensitive cells to hypoxia-insensitive cells. Although precise quantification of 5fC and 5caC is difficult, the enhanced ELISA is capable of precisely determining as low as 1.7% of genomic 5mC and 0.027% of genomic 5hmC in HeLa cells
(Figure 2.6), which is in excellent agreement with previous reports and validates the developed ELISA method.
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Figure 2.5 Multiplex quantification of 5mC, 5hmC, 5fC, and 5caC indicates a hypoxiainduced active DNA demethylation. (A) Normalized quantities of these four DNA methylation marks from enhanced ELISA. (B) Enzymatic pathway for active DNA demethylation.

Figure 2.6 Quantitative changes of 5mC and 5hmC under hypoxia.
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2.3.2

MBD3 Detachment as Putative Indicator for Active DNA Demethylation

The diffusion characteristics of MBD3-GFP in normoxia cells were determined by
FCS: 14.49 ± 0.40 ms in nucleus and 3.10 ± 0.27 ms in cytoplasm. The much slower diffusion in nucleus, as expected, was due to the association with DNA methylation site and
other epigenetic co-factors. The diffusion rate of MBD3-GFP was further compared when
hypoxia or 3 µM decitabine treatment (agent inducing passive DNA demethylation) (Figure 2.7) was applied. Decitabine achieves a demethylation effect by incorporation into the
newly synthesized DNA strand and trapping DNMT1, and so it would not influence the
already bound MBD3 in a relatively short time (e.g., within one to two cell cycles). Consistently, after 1 day treatment with decitabine the average diffusion time of MBD3-GFP
(13.43 ± 0.57 ms) was nearly the same as in control condition whereas a significantly
faster diffusion time (9.89 ± 0.54 ms) was observed in hypoxic cells after 20 hours (Figure 2.8).

Figure 2.7 FCS measurement for the MBD3-GFP diffusion in single living cells. (A) Data were collected from cell compartments with a proper MBD3-GFP expression, followed
by fitting with (B) 3D diffusion models and (C) MEMFCS.
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Figure 2.8 Summary of the MBD3-GFP diffusion times (mean + S.E.M., n > 50). Statistical significance was determined by ANOVA (p = 1.35 × 10-8).

2.3.3

Diffusion of MBD3 in Hypoxia-Sensitive and Hypoxia-Insensitive Cells

Following establishing the MBD3 diffusion as an indicator for active DNA demethylation, further experiments were performed to inspect its detailed behavior during the
period of hypoxia. Interestingly, based on the MBD3 diffusion, two groups of cells can
be distinguished in the first 4 hours of hypoxia. Despite that the majority of cells did not
show a radical MBD3 detachment (diffusion time is about 14 ms), in ~30% of the cells
the diffusion time of MBD3 displayed a steep reduction (diffusion time = 2.95 ± 0.36 ms).
From the microscopic images, the latter group of cells exhibited the morphological properties akin to acutely damaged cells (Figure 2.9A), which was later confirmed by the propidium iodide (PI) uptake experiment (data not shown). Hence, these cells were termed
as hypoxia-sensitive cells. Since the viscosity of nucleoplasm is nearly identical to that of
cytoplasm,94 it can be inferred that MBD3 quickly and completely dissociated from the
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DNA binding sites in hypoxia-sensitive cells. On the contrary, the diffusion of MBD3 in
other hypoxia-insensitive cells experienced a mild and gradual detachment process, as
inferred from the slow shift in the distribution of diffusion times (Figure 2.9B). Even after 24 hours, MBD3 in these cells did not seem to be fully detached (diffusion time =
9.80 ± 0.75 ms) (Figure 2.9C). This phenomenon indicates a gentle weakening of the
MBD3-DNA association, probably due to a retard activation of the demethylation pathway (i.e., time required for an enhanced expression of TET and TDG proteins by hypoxia-inducible factors or pathways). Taken together, it can be concluded that the hypoxiainduced active DNA demethylation leads to different diffusivities of MBD3 based on the
cell state and susceptibility. Hypoxia-sensitive cells predominantly contribute to the initial, massive DNA demethylation in the population while hypoxia-insensitive cells are
involved in the long-term, chronic DNA hypomethylation. Notably, the detachment of
MBD3 serves as a sensitive measure of active DNA demethylation that could result in a
premature cell death, especially to hypoxia-sensitive cells. Starting from the plateau period, the counts representing fully detached MBD3 in FCS measurements substantially decreased from ~30% to ~10% (Figure 2.9C, inset), implicating the elimination of severely
damaged cells from the population.
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Figure 2.9 Time-course change of the MBD3 diffusion in hypoxia-sensitive and hypoxiainsensitive cells. (A) Morphology of the cells responding variedly to hypoxic stress. (B)
The gradual shift of the MBD3 diffusion in hypoxia-insensitive cells. (C) Summary of the
diffusion characteristics (by ANOVA tests). Percentage of the measurements representing
hypoxia-sensitive cells is provided (inset).

2.4

Discussion

Even though global DNA hypomethylation has been characterized as one of the typical epigenetic events that drive a cancerous transformation, increased research emphasis

41
has been placed on the mechanistic understanding of promoter hypermethylation in tumor
suppressor genes. As the oxidation of 5mC and its role in DNA demethylation is being
elucidated, scientists start to recognize that the dynamic turnover of DNA methylation
plays a pivotal role in embryogenesis, differentiation, and oncogenesis. This notion raises
the necessity of inspecting DNA demethylation in single living cell.
Utilizing single-molecule fluorescence techniques, this study paves the way for studying active DNA demethylation by monitoring the diffusion rate of MBD3 in real time,
which is also the pioneering report on the spatiotemporal behavior of MBD proteins in
single living cells. In contrast to other MBD proteins that have an nM-level dissociation
constant (Kd) with DNA methylation site, the Kd between MBD3 and its binding substrate
is at the µM level.35 Hence, MBD3 is more sensitive to be detached from chromatin in the
cells exposed to a triggering stimulation for active DNA demethylation, while the in vivo
binding substrates preferred by MBD3 needs further investigation. FCS has the quantitative ability to sense minute changes in the diffusion of intracellular biomolecules and thus
is a fitted tool to explore the dynamics of DNA demethylation. Under acute hypoxia, active DNA demethylation is initially characterized by an intense detachment of MBD3 in
hypoxia-sensitive cells, leading to the first demethylation peak and premature cell death
within the first 4-8 hours. In hypoxia-insensitive cells the demethylation process is more
relaxed as reflected by the gradual increase in the MBD3 diffusion. To maintain a natural
cell state and function, all cytosine derivatives have to be maintained at a tolerable level,
partly achieved by the protection by MBD3 at relevant sites. Previous studies have shown
that depletion of MBD3 could cause the mice to die in early embryogenesis, signifying
the importance of MBD3 in sustaining the overall abundance of DNA methylation.44 Fu-
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ture research may be focused on obtaining a high-resolution distribution landscape of all
MBD proteins in the human genome and determining the MBD-dependent susceptibility
to active DNA demethylation. In addition, the connections among epigenomic reshaping,
hypoxic tolerance, and oncogenic evolution await more in-depth research (Figure 2.10).

Figure 2.10 Influence of hypoxia on DNA methylation and the fate of cancer cells.

As the sophisticated DNA demethylation network is becoming more understood, it
elicits a relevant question: does the hypoxia-induced demethylation reaction terminates at
5hmC? In human cells the removal of 5hmC could be processed by two possible mechanisms: 1) through deamination of 5hmC to 5hmU (5-hydroxymethyluracil) by AID and
APOBEC enzymes, followed by BER; 2) or the TET-TDG-mediated oxidation and BER.
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Evidently, data from enhanced ELISA supports the latter pathway in that 5hmC, 5fC, and
5caC are concurrently reduced along with 5mC. Moreover, the detachment of MBD3 indicates the TDG-mediated BER that involves a physical removal of cytosine derivatives.
However, which specific TET proteins involved in this process remains to be identified.
Previously, most of the cancerous hypomethylation were found in the short and long interspersed nuclear elements (SINEs and LINEs) as well as repeat sequences that were
long thought as non-coding “junk” DNA.95, 96 Revealed by the Encyclopedia of DNA Elements (ENCODE) project in 2012, nearly 80% of the human genome is actually functional,97 necessitating re-interrogation of the epigenetic state at these regions. In recognition of that the patterns of DNA hypomethylation could be largely varied in different
cancers, an emerging thought is to study the DNA demethylation in a locus-specific manner so that targeted intervention or therapy can be designed. To fulfil this, methodologies
to capture the key moments in a demethylation event and to differentiate heterogeneous
cellular responses are of great value.
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CHAPTER 3. BEHAVIOR AND FUNCTION OF MBD3 IN DNA METHYLATION
HOMEOSTASIS

3.1

Introduction

DNMTs are responsible for adding methyl marks to CpGs; however, the traditional
view of classifying the three major human DNMTs to maintenance DNMT and de novo
DNMT appears to be challenged by cumulative evidence that expounds on a considerable
overlap between their functions,98-100 which in turn inspires a revisiting of the existing
knowledge about the DNA methylation homeostasis. Over the past decade it has been
observed that the maintenance of DNA methylation rarely follows a rigorous CpG-byCpG fidelity, but adopts a stochastic model in which only the average density of DNA
methylation within a certain region of sequence needs to be conserved.101, 102 To achieve
a balance, the twin forces of methylation and demethylation contend in equilibrium but
also work by side. Although the TET family proteins are the only enzyme that catalyzes
the active DNA demethylation in mammalian cells, they primarily enrich in germ cells
and early embryogenesis instead of in somatic cells.103 In light of this, it is of great interest to resolve the question on whether additional factors or machineries exist to facilitate
the precision of maintenance methylation with limited TETs as well as to prevent a possible over-methylation by DNMTs in the DNA methylation homeostasis.
MBD3 belongs to a family of nuclear proteins in close relation to DNA methylation,
but it involves quite different chromatin association and regulatory mechanisms as com-
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pared with other MBD proteins.44, 104 In spite of sharing over 70% of its sequence with
MBD2, MBD3 was found not to be a strong binding protein for 5mC.33, 105, 106 In fact, as
a constitutive component in the Mi-2/NuRD complex, MBD3 preferentially localizes at
CG-rich promoters and enhancers relating to active genes whose methylation state is
poised to frequent turnovers.107, 108 More interestingly, it has been reported that overexpressing MBD3 could induce a global DNA demethylation,42, 109 and a co-localization of
MBD3, MBD2 and DNMT1 could appear at the DNA replication foci to associate with
hemi-methylated DNA.110 These intriguing findings motivate this study to re-evaluate the
underpinning functions of MBD3 in the DNA methylation homeostasis.
In previous chapters, the potency of single-molecule techniques in uncovering epigenetic dynamics was introduced and the diffusion characteristic of MBD3 was successfully correlated with active DNA demethylation by FCS. In this chapter, a comprehensive
set of single-molecule fluorescence tools is applied to dissect the behavior of MBD3 from
the cell cycle perspective. The research hypothesis regarding the MBD3-MBD2-DNMT1
cooperation lies in the in vivo demethylating potential of MBD3 to buffer the activity of
DNMT1 during DNA replication as contributing to the epigenetic inheritance of a locispecific methylation pattern.
In order to obtain an in-depth understanding, several biophysical attributes of MBD3
are characterized – intracellular dynamics, chromatin association, binding stoichiometry,
and molecular interactions in each stage of the cell cycle. Fluorescence lifetime correlation spectroscopy (FLCS), an elegant derivative of FCS, is first used to quantify the realtime diffusion of MBD3 in different cell phases and the results suggest that MBD3 has
distinct binding partners in the G1-phase and G2-phase. Furthermore, the DNA-binding
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stoichiometry of MBD3 is analyzed by PCH that corroborates a salt-dependent “two-site
sequential binding” mode in the G1-phase nucleus. In the G2-phase, the co-localization
of MBD3, MBD2, and DNMT1 is verified with FLIM-FRET. When depleting MBD3 by
siRNAs, the global DNA methylation increases along with promoter hypermethylation in
a number of cell cycle-related genes. Altogether, this work constitutes a pioneer effort to
revise the model of the DNA methylation homeostasis and paves the way for future research aimed to better interpret the epigenetic inheritance.

3.2
3.2.1

Methods and Materials
Cell Cycle Synchronization

G1-enriched HeLa cells were obtained by treatment with 400 µM L-mimosine for
20-24 h. To achieve a maximum of S-phase population, cells were blocked with 2 mM
thymidine for 20 h and released in fresh medium for 10 h, followed by another 20 h thymidine blocking and then culturing with fresh medium for 2-6 h (early S-phase: 2 h; middle S-phase: 4 h; late S-phase: 6 h). Culture of G2-arrested cells was obtained by incubation with fresh medium containing 0.1 µg/mL Colcemid (Life Technologies) for 6 h after
two rounds of thymidine blocking. Flow cytometry was used to validate the cell cycle
synchronization.111 In general, cells were fixed with 70% ethanol first and stained with
PBS buffer containing 20 µg/mL PI, 0.1% Triton X-100, and 200 µg/mL RNase A. The
fluorescence intensity of PI in each single cell was determined by a FC500 MPL system
(Beckman Coulter). At least 15,000 cells were collected for one measurement and the
generated cell cycle histogram was fitted by the Watson pragmatic model in the Flowjo
software (Figure 3.4A).
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3.2.2

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

Total RNA was extracted and reverse-transcribed with RNeasy Mini Kit (Qiagen)
and iScript cDNA Synthesis Kit (Bio-Rad), respectively. Before cDNA synthesis, the genomic DNA was removed by DNase I. PCR reaction was performed in a StepOnePlus
system using SYBR Green PCR Master Mix (Life Technologies). ∆∆Ct method was used
to normalize the transcription of target genes to the internal control gene GAPDH. The
PCR primers for GAPDH, DNMT1, DNMT3A, and DNMT3B were designed with the
Primer-BLAST online tools (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).
Table 3.1 PCR primers used in Chapter 3
GAPDH
DNMT3A
DNMT3B
DNMT1
MBD3112

(F)CAGCCTCAAGATCATCAGCA
(R)TGTGGTCATGAGTCCTTCCA
(F)TATTGATGAGCGCACAAGAGAGC
(R)GGGTGTTCCAGGGTAACATTGAG
(F)GGCAAGTTCTCCGAGGTCTCTG
(R)TGGTACATGGCTTTTGGATAGGA
(F)TACCTGACGACCCTGACCTC
(R)CGTTGGCATCAAAGATGGACA
(F)GGCCACAGGGATGTCTTTTA
(R)TTGACCTGGTTGGAGGAGTCG

3.2.3

FLCS and PCH

In FLCS, separating the “genuine” molecular diffusion from the overall fluctuation is
achieved by deconvolution of the TCSPC histogram with a multi-exponential model:
n

I (t ) = ∑ ai ⋅ e

−

t

τi

i =1

where τi is the characteristic decay lifetime of the ith component and ai is its amplitude. A
filter function is applied to assign the probability contribution of a single photon to the
autocorrelation function for the ith component with an optimal weight determined by its
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TCSPC channel number j. For a given channel j:

∑

L
i =1

f j( i ) = 1 , where L is the number of

components, and the weight for each component could have an absolute value greater
than 1 or be a negative value. These filter functions are numerically calculated by a matrix derived from the measured fluorescence intensity Ij and the decay pattern p (ji ) .113
Hence, the autocorrelation function for a specific species (i) can be expressed as:
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Taking advantage of the TCSPC filtering, a distorted autocorrelation fluctuation due
to the detector noises (e.g., thermal noise, afterpulsing) and other parasitic noises (e.g.,
elastic and Raman scattering) occurring at the millisecond level can be effectively removed.114, 115

Figure 3.1 TCSPC filter function eliminates the impact of the short-timescale noises to an
autocorrelation function.

The basic theory and working mechanism of PCH is elaborated in Chapter 1.2.2. To
test the PCH algorithm, Cy3 tetramer was successfully differentiated from Cy3 monomer.
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In this experiment, a ten-fold concentrated solution of Cy3 monomers was prepared and it
was impossible to distinguish it from the tetramer solution by simply comparing the ensemble fluorescence intensities (otherwise the average brightness could give out an opposite conclusion). However, by mathematically eliminating the influence from the concentration difference, the single-molecule brightness of Cy3 tetramers was determined to be
almost four times of that of Cy3 monomers, thus verifying the power of PCH.

Figure 3.2 In vitro demonstration of PCH. Ensemble fluorescence traces (left panel) with
an integration window of 50 µs are translated to photon counting histograms followed by
fitting with super-Poissonian algorithm (right panel), yielding single-molecule brightness.

3.2.4

Immunofluorescence and FLIM-FRET

Considering the sensitivity of FRET to the inter-molecule distance, to minimize the
size effect from antibodies (~10 nm), the primary antibodies (anti-MBD1/MBD2/MBD3IgG, Abcam; anti-DNMT1-IgG, Novus Biologicals; anti-5hmC/5fC/5caC-IgG, Active
Motif) were directly labeled with the FRET-pair dyes including: MBD3-Alexa488 (donor)
and MBD1/MBD2/DNMT1/5hmC/5fC/5caC-Alexa555 (acceptor) by using APEX Antibody Labeling Kits (Life Technologies). For immunofluorescence staining, cells were
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fixed with 4% ice cold paraformaldehyde (PFA) for 15 min and then rinsed three times
with clean PBS buffer. Cell membrane was permeabilized with 0.4% Triton X-100 for 30
min followed by rinse for 15 min. To stain 5hmC, 5fC, and 5caC, DNA was denatured by
1 N hydrogen chloride at 37°C for 30 min. Cells were then blocked with PBS containing
5% goat serum and 0.3% Triton X-100 for 1 h at room temperature. Primary antibodies
were diluted 50-100 times in PBS containing 1% BSA and 0.3% Triton X-100 (to a concentration of ~5 nM) and incubated with cells overnight at 4°C. In the next day cells were
rinsed 3 times with fresh PBS prior to FLIM imaging. The FLIM-FRET theory and instrumentation are elaborated in Chapter 1.2.2. For a 150 × 150 pixels FLIM image obtained from one scanning, the laser dwelling time at each pixel is about 0.8 ms that is far
longer than most fluorescence lifetimes (ns-level). TCSPC can be generated from a single
pixel or all the pixels in an image (Figure 3.3B); hence the FLIM measurement can reach
single-molecule resolution if few fluorophores exist in one pixel.

3.2.5

Co-Immunoprecipitation (Co-IP) and Western Blot

Co-IP was conducted with the Pierce Co-IP Kit (Thermo Fisher Scientific) referring
to an established protocol.116 In brief, anti-GFP monoclonal antibody (primary amine-free,
Pierce) or control IgG was first immobilized using the AminoLink Plus coupling resin. 5
× 106 cells transfected with MBD3-GFP in different cell phases were lysed (25 mM Tris,
150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol; pH = 7.4) and about 1.5 mg precleared lysate was incubated with the antibody-coupled resin at 4°C overnight. After elution, the sample was analyzed by Western immunoblotting. The input proteins were separated by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
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followed by membrane transferring and incubation with the primary antibodies. The final
signal was developed by Pierce Fast Western Blot Kit and SuperSignal West Pico Substrate.

3.2.6

Transfection of siRNA and Methylation Analysis

MBD3 siRNA, scrambled siRNA, and transfection reagents for knockdown experiments were obtained from Santa Cruz Biotechnology. 50 pmol siRNA was used for a 35
mm Petri dish in which cells reached 70% confluence, according to the manufacturer’s
instruction. Transfection lasted for 24 h followed by sub-culturing with normal fresh medium for another 72 h. DNA from control and siRNA-treated cells was extracted and purified with DNeasy Blood & Tissue Kit (Qiagen), according to the manufacturer’s instruction. Global DNA methylation was quantified with MethylFlash Methylated DNA
Quantification Kit (Epigentek). Briefly, 100 ng DNA was deposited to the bottom of the
assay well and incubated with capture antibody and detection antibody, sequentially. The
final colorimetric signal was normalized to a standard input DNA to calculate the global
methylation percentage. 22 genes participating in cell cycle progression were assessed for
their promoter CGI methylation by using EpiTect Methyl II Signature PCR Array (Qiagen). The working mechanism for this assay is to digest an equal amount of DNA with
methylation-sensitive endonuclease (the unmethylated DNA will be eliminated) or methylation-dependent endonuclease (the methylated DNA will be eliminated). Upon a PCR
amplification with specific primers targeting the characterized CGIs of the chosen genes,
the ratio of methylated promoters to unmethylated promoters in the sample DNA can be
determined.
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3.3
3.3.1

Results

Localization Preference and Cell Cycle-Dependent Expression of MBD3

The localization preference of endogenous MBD3 was first probed via FLIM-FRET,
to explore the association of MBD3 with the active demethylation products (i.e., the 5mC
derivatives). From the results, a relatively weak interaction between MBD3 and 5hmC
was noted while MBD3 exhibited a prominent co-localization with 5fC and 5caC (Figure
3.3), which is consistent with the recent findings using conventional methods.106,

117

However, this cannot fully rule out the possibility of MBD3 as a reader protein for 5hmC
because: 1) FRET could be influenced by other factors such as the donor-acceptor orientation; 2) the MBD3-5hmC interaction requires some other co-factors that might block or
separate the antibody recognition sites or 3) this connection might be cell type-specific.105
Nevertheless, this set of experiments provides partial evidence to the assumption that
MBD3 associates with the CpGs experiencing active transition in their methylation state.
This demethylation potential could be ascribed to the MBD3-mediated further recruitment of TET proteins or a steric hindrance to impede the DNMTs catalysis.
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Figure 3.3 Localization preference of MBD3. (A) FLIM images of double-stained cells
with directly labeled primary antibodies. (B) Fluorescence lifetime can be determined by
fitting the TCSPC from the whole image (left panel), or single pixels to generate a histogram (right panel). (C) FRET efficiencies between MBD3 and different 5mC derivatives.

Next, the transcription of DNMTs and MBD3 in different cell phases was quantified.
The qRT-PCR results show that all DNMTs start to increase in the S-phase and maintain
their abundance till the G2-phase (Figure 3.4B), which validates the cell cycle-dependent
expression of DNMTs.118 Although it is expected that the transcription of DNMTs should
peak during the S-phase rather than in the G2-phase, two critical points to bear in mind
are that 1) the DNA maintenance methylation is a delayed event subsequent to DNA replication119 and 2) in cancerous or transformed cells (e.g., HeLa cells here) the regulation
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of DNMTs could become more lagged due to rapid cell proliferation. Interestingly, accompanying with all DNMTs, the transcription of MBD3 also experiences a cell cycledependent enrichment. This concurrent transactivation provides preliminary support for a
possibly underlying contention or cooperation between MBD3 and DNMTs in the DNA
methylation homeostasis.

Figure 3.4 Expression of MBD3 is concurrent with DNMTs in cell cycle. (A) Cells enriched in each cell phase were harvested for qRT-PCR. (B) Transcriptional levels are presented as mean with standard deviation (n = 4). One-way ANOVA was used to determine
the statistical significance.

3.3.2

The Mobility of MBD3 is Increasingly Constrained during the G1-S-G2 Transition

After transfection, the intracellular diffusion of MBD3-GFP was characterized by
FLCS. In non-synchronized cells, the diffusion rate of MBD3-GFP in cytoplasm is found
to be much faster (diffusion time = 3.6 ± 0.4 ms) than that in nucleus (diffusion time =
16.2 ± 1.9 ms), which is in agreement with the results in Chapter 2. The restricted diffu-
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sion of MBD3-GFP in nucleus could be attributed to two mechanisms: 1) integration into
the larger Mi-2/NuRD complex and 2) association with the targeting chromatin site. The
cell cycle-dependent diffusion of MBD3-GFP was then determined. Compared to MBD3GFP in the G1-phase cells, MBD3-GFP in the S-phase and the G2-phase cells exhibits a
drastically slower diffusion: diffusion times are 11.5 ± 0.6 ms (G1), 26.6 ± 1.3 ms (S),
and 36.9 ± 2.1 ms (G2), respectively (Figure 3.5C). Moreover, an incremental adjustment
for anomalous diffusion was noted in fitting the autocorrelation functions from the G1 to
S and G2 transition, indicating a strengthened chromatin interaction. Considering that the
molecular diffusion is negatively proportional to the hydrodynamic radius, the data from
FLCS suggests that, starting from the S-phase, the MBD3-NuRD complex may further
associate with or recruit other biomolecules to relevant loci, which results in an enhanced
DNA-binding affinity.
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Figure 3.5 The mobility of MBD3 is increasingly restricted during the cell cycle progression. (A) FLCS data collection points from different cell compartments. (B) Autocorrelation functions in different cell phases were obtained from cytoplasm (upper) and nucleus
(lower). (C) Summarized diffusion statistics and significance test by ANOVA. Each column represents data from more than 15 cells (mean + S.E.M., n > 30).

3.3.3

The DNA-Binding Stoichiometry of MBD3 Undergoes a Transition during the SPhase

Following FLCS, the average single-molecule brightness of nuclear MBD-GFP was
evaluated by PCH, which uncovered a gradual reduction in the copy number of MBD3GFP molecules along with the cell cycle progression (Figure 3.6A). To calibrate the GFP
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brightness from different stoichiometry, a series of controls were included: monomeric
GFP in solution and in cell nucleus, toll-like receptor 9-GFP (TLR9-GFP), and MBD1GFP in live cells. In vitro GFP monomers were measured to establish the baseline brightness that is 1341 ± 48 cpsm (counts per second per molecule) under a 2.5 µW excitation
power (Figure 3.6B). Based on this value, about 8% of nonspecific dimerization was determined in living cell nucleus. Then the obtained brightness from dimerizable proteins
could be assigned to a proper composition of monomers and dimers. Referring to previous reports, TLR9-GFP and MBD1-GFP were respectively chosen as dimer and monomer controls.120 From the PCH calculation, the dimer percentages for TLR9-GFP and
MBD1-GFP are 78% and 2% in HeLa cells, irrespective of cell phases. Notably, the dimer percentage of MBD3-GFP implicates that its composition stoichiometry experiences
a cell cycle-dependent transition: from 84% in the G1-phase to 48% in the S-phase, and
eventually to 16% in the G2-phase (Figure 3.6C). According to a recent study, MBD domain was able to dimerize at a single methylated CpG and this stoichiometric pattern was
salt/cation-dependent.121 It was thus proposed that a low-salt environment could undermine the dimerization of MBD3 in living cells. By culturing G1-phase cells in hypotonic
medium, the dimer proportion of MBD3-GFP was indeed reduced (Figure 3.6D). In the
hypothesis of this study, the stoichiometric transition of MBD3 in cell cycle is driven by
the cooperation among MBD3, MBD2, and DNMT1 in the DNA maintenance methylation, which can be combined with the FLCS findings: during the cell cycle progression,
MBD3 is gradually incorporated into a larger protein complex (inferred from the slowed
diffusion rate) so that gains a stronger binding affinity with chromatin (inferred from the
increasing anomalous diffusion behavior). This single-molecule behavior implies that the

58
difference between the inter-molecule bonding strengths of MBD3-DNA and MBD3MBD2-DNMT1 mechanistically advance the stoichiometric transition, for which the intracellular microenvironment (e.g., local salt ions) may play a pivotal role.

Figure 3.6 Single-molecule brightness analysis implicates a stoichiometric transition of
MBD3. (A) PCH from nuclear MBD3-GFP in different cell phases. (B) Brightness of different GFP tagged proteins: pure GFP is the baseline control, TLR9-GFP is the dimer
control, and MBD1-GFP is the monomer control. (C) Dimer percentage for each protein
is calculated. (D) Hypotonic medium disrupts the dimer formation of MBD3-GFP in the
G1-phase nucleus.

3.3.4

MBD3, MBD2, and DNMT1 Act in Concert in DNA Maintenance Methylation

Despite that a number of methods, including Co-IP, affinity electrophoresis, pulldown assay, and two-hybrid screening, are available for evaluation of molecular interactions; a grand challenge is on how to directly visualize such in situ information in its original context. Super-resolution optical microscopy has overcome the diffraction limit im-
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posed by the physical law to achieve a sub-200 nm resolution for single-cell imaging, but
the spatial scale (< 10-20 nm) for most protein-protein and protein-DNA interactions is
still beyond that “super-resolution” scope. Hence, in this study FLIM-FRET was employed as a finer measure to probe the MBD3-related co-factors at the 10 nm scale. By
directly labeling the primary antibodies, HeLa cells were double-stained and measured by
FLIM in different cell phases (Figure 3.7A). As expected, a cell-cycle dependent occurrence of FRET was noted in both the MBD3-MBD2 and the MBD3-DNMT1 combinations, indicating a growing proportion of MBD3, MBD2, and DNMT1 assembled into a
larger complex. In the G1-phase, MBD3-Alexa488 in the presence of MBD2-Alexa555
has a slightly shorter lifetime (3.34 ± 0.06 ns) than that in the presence of DNMT1Alexa555 (3.45 ± 0.06 ns) (Figure 3.7B), confirming that some of the endogenous
MBD3-MBD2 co-localization is cell cycle-independent.5, 122 In the control combination,
no FRET signal was detected between MBD3-Alexa488 and MBD1-Alexa555 (Figure
3.8). In parallel, all these interactions were validated by conventional Co-IP (Figure 3.7C).
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Figure 3.7 Co-localization of MBD3-MBD2-DMNT1 was assessed by FLIM-FRET. (A)
Labeled primary antibodies were applied to target the protein pairs (i.e., MBD3-DNMT1,
MBD3-MBD2). FLIM images of MBD3-Alexa488 were obtained in different cell phases,
with DNMT1 or MBD2 labeled by Alexa555. (B) Fluorescence lifetimes are presented
with mean and stand deviation (n = 10 images), based on which FRET efficiencies can be
calculated (inset). (C) Results from FLIM-FRET were validated by Co-IP.
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Figure 3.8 MBD3 and MBD1 are not interactive in cell cycle. (A) Double staining was
performed with directly labeled antibodies. (B) FLIM of MBD3-Alexa488 was collected
in different cell phases.

3.3.5

Insufficiency in MBD3 Disrupts DNA Methylation Homeostasis

To inspect the functional involvement of MBD3 in the DNA methylation homeostasis, a group of siRNAs specifically targeting the MBD3 expression were introduced into
HeLa cells. Given the findings that MBD3 facilitated a hypomethylation for its binding
sites, it was expected that cells would experience a global hypermethylation when MBD3
was knocked down. Using quantitative immunoassay, the global level of DNA methylation in knockdown cells was found to increase from 1.66% to 2.34% after 72 hours (Figure 3.9B). Afterwards, the methylation levels of promoter CGIs in 22 cell cycle-related
genes were evaluated since MBD3 has been discovered to regulate the cell cycle progression.123 The promoter CGIs of the selected genes, except BRCA2 and RAD9A, were de-
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termined to be extensively hypomethylated or unmethylated in HeLa cells, consistent
with the ENCODE dataset (retrieved from https://genome.ucsc.edu/) and previous literature.124 After the MBD3 expression was suppressed, a ubiquitous elevation in the methylation of assessed CGIs was observed, though some changes were relatively subtle perhaps due to the short period of knockdown (Figure 3.9C). In parallel, the global demethylation caused by overexpression of MBD3 was also confirmed (Figure 3.9). Concerning
the importance of MBD3 to the Mi-2/NuRD function and DNA maintenance methylation,
the cell cycle progression is subjected to dysfunction when MBD3 is deregulated. Therefore, the cell-phase distribution was re-examined and it indicated a difficulty for MBD3insufficient cells to pass the G1/S checkpoint (Figure 3.9D), resembling a G1-phase arrest
upon depletion of Mi-2/NuRD or DNMTs.125-127 Overall, this line of results supports the
hypothesis that the demethylating potential of MBD3 plays a critical role in sustaining
the DNA methylation homeostasis and cellular functions.
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Figure 3.9 Insufficiency in MBD3 disrupts the DNA methylation homeostasis. (A) The
MBD3 siRNAs were introduced to HeLa cells for knockdown. (B) 72 hours after knockdown, the global DNA methylation was determined with immunoassay (n = 3), (C) the
promoter CGIs methylation of 22 cell cycle-related genes was quantified with PCR arrays
(n = 3), and (D) the cell cycle distribution was examined with flow cytometry.

Figure 3.10 Overexpression of MBD3 causes global DNA hypomethylation.
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3.4

Discussion

Achieving the DNA methylation homeostasis necessitates the interplay amidst multiple molecules and mechanisms. For a single nucleosome that covers about 200 bp DNA
(including the linker), statistically 3-10 CpGs are included and the average extent of
methylation marks should be inherited over generations. In order to retain such a steady
methylation for a given region, a unified stochastic model was recently proposed102:

dθmi
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be roughly defined: f main
∝ rDNMT
1 × rMBD 2 , rmet ∝ rDNMT 3 A + rDNMT 3 B , rdemet ∝ rTETs × rMBD 3 . In

the G1-phase, MBD3 tends to locate at the active genes and protect their hypomethylated
status to avoid DNMT3 invasion. In the S-phase and G2-phase, DNMT1 – together with
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DNMT3 – accomplish the DNA maintenance methylation, whereas no experiments have
observed the real-time participation of TETs in this process. Yet without a protective or
proofreading mechanism, the delicate DNA methylome would be fairly vulnerable to a
i
non-equilibrium whenever DNMT1 overacts (i.e., f main
> 1 ). In line with previous reports,

this study reveals the dynamic behavior of MBD3 and its importance to the DNA methylation homeostasis: when cells enter cell cycle, a proportion of MBD3 and MBD2 would
co-localize with DNMT1 to offer a regulatory “symbiosis” for the ongoing DNA maintenance methylation (Figure 3.11A). As newly discovered methylation derivatives, 5fC and
5fC emerge to have their independent regulatory functions,128, 129 and one potential function for MBD3 in the DNA methylation homeostasis is to mark their existence on the parental DNA strand and pass down to the daughter strand (Figure 3.11B). Besides DNA
methylation, the MBD2/3-associated Mi-2/NuRD can further facilitate nucleosome remodeling and histone modification in the newly synthesized chromatin. Also in light of
the uncovered dynamic behavior of MBD3, it can be inferred that the occupancy sites by
MBD3 are varied in different cell phases, which may explain the divergent observations
about the genome-wide MBD3 distribution in previous researches.
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Figure 3.11 Dynamic behavior of MBD3 in the DNA methylation homeostasis. (A) In the
G1-phase, MBD3-NuRD adopts a “two-site sequential binding mode” at its binding CGIs
and maintains a hypomethylated state. kd1 and kd2 denote the two dissociation constants
for the homodimer. As DNA starts to replicate, the newly synthesized hemi-methylated
DNA intends to inherit the methylation density from the parental template, catalyzed by
DNMTs (mainly DNMT1). A proportion of MBD3 and MBD2 would cooperate with
DNMT1 to complement the maintenance accuracy. kd3 denotes the dissociation constant
for the heterodimer. (B) When MBD2 and DNMT1 are re-establishing the landscape of
5mC, the demethylating potential of MBD3 can facilitate preserving those 5mC derivatives (i.e., 5hmC, 5fC, and 5caC), providing a balancing force in the DNA methylation
homeostasis.

The core region sequence for DNA recognition and binding is highly conserved
among human MBD members. To date some already identified residues critical for the
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MBD-DNA coupling include VAL20, ARG22, LYS30, TYR34, ARG44 and SER45,32, 33
in which the arginine residues determine a hydrogen bond and cation-π interaction-based
“stair motif” association with CpGs.34 Although MBD3 is highly identical to MeCP2 and
MBD2 in that core region, the two residual mutations (K30H and Y34F) at the binding
interface undermine the interaction specificity between MBD3 and 5mC. Corresponding
to a recent research showing that MBD3 preferably localizes to the active epigenetic loci,
such as enhancers and promoters, herein the FLIM-FRET approach confirms an in situ
interaction between MBD3 and the 5mC-oxidized derivatives (i.e., 5hmC, 5fC and 5caC
that are difficult to be detected with traditional DNA-sequencing methods), to support the
participation of MBD3 in the DNA demethylation and gene activation.
The binding stoichiometry between MBD domain and its targeting site was elusive
and even controversial as in different studies. Until very recently, a “two-site sequential
binding mode” has been biochemically evaluated and it demonstrated that the MBDmediated DNA binding would tolerate a homodimeric stoichiometry at a single CpG but
with dissimilar dissociation constants: approximately 80 nM for the first MBD and 5 µM
for the second one.121 Moreover, a low salt concentration could substantially compromise
the MBD to differentiate (methylated)CpG from random DNA sequences as monovalent
cations are crucial to suppress the non-specific binding. This explains why the homodimeric state of MBD3 in the G1-phase got significantly depleted when a hypotonic medium was applied. On the contrary, MBD1 was found to exist predominantly in a monomeric state, which might be due to the distribution of MBD1 in the highly condensed heterochromatin where the low-affinity dimerization is physically hindered. One interesting
finding requiring future elucidation is about the MBD3 stoichiometric transition from the
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G1-phase to the G2-phase, if this transition is not only enforced by a mechanical separation along with the double-helix disentanglement in the S-phase. Theoretically, the cooperation of MBD2-MBD3-DNMT1 aids in achieving the homeostatic DNA maintenance
methylation, while the detailed mechanism to form such a multi-component complex is
challenging to resolve. MBD2 and DNMT1 have a structural base to co-localize because
they could firmly bind with hemi-methylated DNA. For a further incorporation of MBD3,
additional actions might be needed. One is through other epigenetic modifications such as
histone acetylation. MBD2, in the context of Mi-2/NuRD, can induce a local histone hypoacetylation to subsequently attract MBD3-NuRD. Another way is through the coiledcoil interaction. The key helix domain to form coiled-coil oligomers is highly conversed
among MBD proteins, though a stable MBD2-MBD3 heterodimer was hard to detect by
gel filtration analysis.130 However, considering the fact that the coiled-coil interaction is
contingent on the protein conformation as well as the surrounding physicochemical factors,131 it cannot eliminate the possibility of a cell cycle-dependent coiled-coil MBD3MBD2 interaction. In addition, as a core subunit in the Mi-2/NuRD, p66α can stably oligomerize with either MBD2 or MBD3,130, 132 an indirect route to link MBD3 and MBD2
could be involved – in the context of a multimer bridged by p66α or other coiled-coil
domain proteins. Notably, the dissociation constant for coiled-coil mediated interactions
can reach the level of ~10 nM (a much stronger affinity than the MBD-DNA binding),
thus conducive to the disintegration of MBD3 homodimers. The primary concern for this
assumption is how the coiled-coil interaction gets inhibited in the G1-phase. Last, in the
process of recruiting biomolecules to achieve the maintenance methylation, the potential
contribution from those classical DNA replication-related proteins, such as PCNA and
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UHRF1, should not be overlooked. Further efforts can be placed in understanding the
triggering mechanism for this stoichiometric transition and profiling the detailed interactome.
From phenotypic studies, MBD3 has been shown to play a deterministic role in embryogenesis,44 pluripotency,133 differentiation,112 reprograming,134 and a variety of diseases,39 highlighting its functional importance. Disrupting the expression of MBD3 unequivocally results in abnormal DNA methylation, but an in-depth exploration is lacking.
This study, combining single-molecule probing with biological experiments, opens a new
window to research the underlying mechanistic connections. The close relation between
MBD3 and DNA demethylation gives rise to a cell cycle-dependent protein behavior and
serve as a pivotal balancing strength to merit the DNA methylation homeostasis. By highlighting the location of 5mC derivatives, this unique feature of MBD3 could not only improve the precision and efficiency of TETs but also constitute a protective mechanism to
buffer the possible overactivity of DNMTs.
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CHAPTER 4. REGULATORY LANDSCAPE AND CLINICAL IMPLICATION OF
MBD3 IN HUMAN MALIGNANT GLIOMA

4.1

Introduction

The deadly form of intracranial malignant gliomas, i.e., the World Health Organization (WHO) grade III-IV tumors, constitutes a heavily socioeconomic and healthcare
burden. Today, even with significant advances in surgery, radiation therapy, and chemotherapy, yet the median survival for glioma patients, especially for those who are diagnosed with the most aggressive glioblastoma multiforme (GBM, grade IV) is extremely
poor. A multitude of factors are involved in gliomagenesis, and so far enormous efforts
have been invested in seeking clinical biomarkers for a better patient stratification and
therapeutic management. As similar in other cancers, genetic mutations, epigenetic aberrations, environmental stress, signaling malfunction, and immunologic dysfunction synergistically contribute to the etiology of human malignant glioma.135-137 For GBM patients receiving gross total surgical resection and effective adjuvant treatments, the 5-year
survival rate is only 0.05% to 4.7% upon diagnosis,138 which imperatively necessitates
more in-depth and comprehensive research.
Although epigenetic aberrations have been uncovered as a driving force in a large
number of human diseases, its mechanistic correlation with malignant glioma is less explored. As a key modulator, DNA methylation, i.e., the addition of a methyl group to the
5-carbon of cytosine, epigenetically dictates the downstream transcription when accumu-
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lating at the CpG island of a gene promoter.4 In the oncogenic process, extensive alterations regarding the quantity and distribution of DNA methylation have been observed.139
Hence, the DNA methylation homeostasis is essential to prevent a cancerous transformation and require a delicate cooperation among numerous molecules and factors, including MBD proteins.140 In contrast to other typical MBD proteins (e.g., MBD2 and
MeCP2) that specifically associate with 5mC for gene repression, MBD3 evolves to gain
a functional diversity. It has been found that MBD3 can either up-regulate or downregulate its influential genes under particular circumstances.107 As a core subunit of the
Mi-2/NuRD complex, MBD3 also participates in the regulation of nucleosome remodeling and histone acetylation.5 In Chapters 2 and 3, the significance of MBD3 in the active
DNA methylation and DNA methylation homeostasis has been explored. Altogether, its
versatile functions render MBD3 a pivotal part in the epigenetic network. Further, considering the importance of MBD3 to brain development and cell differentiation, it will be
of translational value to dissect its implication in human malignant glioma.
In this chapter, the genome-wide transcription regulated by MBD3 and the possible
correlation with the survival of glioma patients are examined. In human glioma cells, the
epigenetic modulation by MBD3 is found to be bidirectional: both active and repressed
genes are involved. By profiling the transcriptomic changes in GBM cells upon MBD3
knockdown (MBD3-KD), it is revealed that the differentially expressed genes (DEGs)
include a myriad of membrane receptors and transcription-related factors. Moreover, several novel relations with regard to tumor malignancy and progression are discovered. For
example, MBD3 is required to facilitate the expression of the major histocompatibility
complex (MHC) class II molecules, which are proposed to be the key proteins in anti-
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glioma immunity.141-143 Furthermore, depletion of MBD3 enhances transcription from the
oncogenic miR-17-92 cluster at chromosome 13, to promote the tumor progression. The
in vitro and in vivo experiments cogently support an anti-proliferative potential of MBD3.
Last, in an attempt to establish MBD3 as a prognostic biomarker, a clinical cohort of glioma patients has been followed up for 60 months. According to the results, a concurrent
enrichment of MBD3 and 5hmC in tumor tissue indicates a better progression-free survival (PFS) and overall survival (OS), which confers promising information for future
large-scale clinical studies.

4.2
4.2.1

Methods and Materials

Cell Culture and MBD3 Knockdown

For the in vitro experiments, human SF767 GBM cells were routinely cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% fetal bovine serum, 1% antibiotics, and 1% glutamate. After revival from liquid nitrogen, the cells subcultured for 4 to 6 passages were used for knockdown experiments. Specific siRNAs targeting human MBD3 mRNA and scramble siRNAs were obtained from Santa Cruz Biotechnology (sc-35867). Transfection was conducted using the recommended siRNA Reagent System (sc-45064). The knockdown effects were determined by qRT-PCR and immunofluorescence staining. From the results, a 70-75% of knockdown efficiency can be
maintained up to 6 days after transfection (Figure 4.2A), based on which microarray, proliferation assay, and migration assay were performed.
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4.2.2

RNA Microarray and Data Analysis

The whole-genome difference in transcriptome between low-grade glioma and GBM,
as well as the DEGs in GBM cells before and after MBD3 knockdown were investigated
with the SurePrint G3 Human Gene Expression 8 × 60K Microarray Kit (Design ID:
028004, Agilent). This array chip covers 27,958 Entrez Gene RNAs and 7,419 long noncoding RNAs (lncRNAs). Four biological replicates or clinical samples were prepared for
each group. With RNA extracted by TRIzol reagent (Life technologies, for biopsy tissues)
or RNeasy Mini Kit (Qiagen, for cultured cells), cDNA and Cy3-labeled cRNA were sequentially synthesized with the Agilent LowInput QuickAmp Labeling Kit. The hybridization step lasted for 17 h at 65°C. After mild wash, the array slides were imaged with a
SureScan scanner followed by feature extraction. The hybridization quality was assessed
by monitoring the spike-in signals of ERCC and E1A control probes. Then the raw fluorescence readouts from the array were normalized to the intensity value of the 75th percentile of all non-control probes. For genes with multiple probes, the expression was numerically averaged. Approximate 2,000 DEGs based on fold-change and p-value (foldchange > 3 and p-value < 0.05 for clinical samples; fold-change > 1.5 and p-value < 0.1
for cultured cells) were determined with moderated t-test in the GeneSpring GX software.
Protein classification was done with PANTHER (http://www.pantherdb.org).144, 145 GO
analysis was performed with GeneSpring GX. The DEGs-involved cellular functions and
diseases were analyzed with the IPA online tool (http://www.ingenuity.com/products/ipa).
The information of differentially expressed lncRNAs was manually annotated and crossverified with referring to:
EMBL-EBI database (http://www.ebi.ac.uk)
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lncRNA database (http://lncrnadb.com)
miRBase (http://www.mirbase.org)
Human lincRNA catalog (http://www.broadinstitute.org/genome_bio/human_lincrnas)
The complete microarray raw data have been deposited to NCBI GEO (GSE79878).

4.2.3

Methylation-Specific PCR (MSP) for the CIITA Promoter IV Region

The methylation status in the promoter IV region of the CIITA gene was determined
by MSP. After DNA extraction and global methylation analysis (see detailed protocol in
Chapter 3.2.6), bisulfite conversion was performed with EZ DNA Methylation-Lightning
Kit (Zymo Research). The PCR primers and reaction condition followed the published
protocol.146 The amplicons from unmethylated primers and methylated primers were run
through 3% agarose gel pre-stained with the GelRed dye (Biotium). The gel band intensity was quantified with the ImageJ software (http://imagej.nih.gov/ij).

4.2.4

Construction of Lentivirus and Cell Transduction

A MBD3 shRNA was designed for the in vivo tumor formation assay. The shRNA (5’
– GCAAGATGCTGATGAGCAAGATG – 3’) was constructed into the pLent-U6-GFPPuro plasmid. Then the psPAX2 and pMD2.G packaging plasmids were co-transfected
with the pLent-U6-GFP-Puro/pLent-MBD3 shRNAs in HEK293ft cells for 48 h according to manufacturer’s instructions. Medium with virus was collected after 48 h of transfection and concentrated by centrifuge. Titer of viruses was tested and then preserved in 80°C. Human U87 GBM cells were infected with the shRNA construct for 48 h and selected with puromycin (0.75 mg/mL). 5 × 106 infected cells (GFP/MBD3 shRNAs) were
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injected to the thalamus of mice (BALB/c-nu, body weight 18-22 g, 1-month old). One
month after injection, the mice were sacrificed and the tumors were taken out for measurement.

4.2.5

Clinical Samples

A panel of primary glioma biopsy samples with characterized WHO grade and normal brain tissues from non-cancer pathologies were obtained from the Department of
Neurosurgery at Xiangya Hospital of Central South University (Changsha, Hunan, China),
with informed consent from all involved patients. By matching their clinical properties,
MBD3 and 5hmC levels, 14 glioma patients were enrolled to the follow-up cohort, and
their basic information was listed in Table 4.1. All patients received surgical resection to
the extent feasible, followed by radiation therapy and chemotherapy which were given
around 2-4 weeks after the first surgical removal. Radiation therapy was given with a
dose of 1.8 Gy/d and a total dose of 50-56 Gy, including 30-36 Gy for brain and spine,
plus 20 Gy for the original tumor site as the local boost. Chemotherapy mainly involved
oral administration of temozolomide. One treatment cycle of chemotherapy was a consecutive administration of 150 mg/(m2·d) for 5 days in every 4 weeks. 8 cycles were given in total. All surgical operations were performed in the Department of Neurosurgery at
Xiangya Hospital; and the radiation therapy and chemotherapy were administered by the
Department of Oncology at Xiangya Hospital. For clinical sample preparation, after a
pathologist confirmed the tumor grade according to the 2007 WHO Classification of Tumors of the Central Nervous System, the tumor DNA and RNA were immediately extracted from the surgically resected tissues and the rest of the tumor was paraffin embed-
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ded. A 60-month follow-up after surgery was conducted: PFS is defined as the living
time before tumor recurrence; OS is defined as the time before clinical death or last follow-up. This study was approved by the Ethic Committee of Xiangya Hospital of Central
South University.
Table 4.1 Information of patients enrolled for the clinical follow-up
Patient #

Gender

Age

Symptoms

Tumor Location

G II_1

Female

37

Seizure

L. frontal

G II_2

Male

36

Headache

R. temporal

G II_3

Female

46

Headache; Visual impairment

L. frontal & temporal

G II_4

Male

42

Seizure; L. limb weakness

R. frontal

G III_1

Male

44

R. limb weakness & numbness

L. frontal & parietal

G III_2

Male

48

Nausea & vomiting

L. temporal

G III_3

Male

62

Visual impairment

R. frontal

G III_4

Male

57

Poor memory; Headache

L. insula

GBM_1

Male

37

Seizure; R. limb weakness & numbness

L. frontal & parietal

GBM_2

Male

58

Headache; Poor memory

R. temporal & insula

GBM_3

Male

27

Headache; Dizziness; Seizure

L. temporal

GBM_4

Male

46

Headache; Visual impairment; Poor memory

L. temporal

GBM_5

Female

55

Headache

L. temporal

GBM_6

Female

26

R. limb weakness

R. frontal & parietal

4.2.6

Dot Blot for 5hmC in Clinical Samples

Genomic DNA from normal brain or tumor tissues was isolated by cell lysis buffer
(100 mM Tris-HCl, pH = 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 0.667 µg/µL proteinase K) at 55°C overnight. In the second day, the samples were added with an equal
volume of phenol:chloroform:isoamyl alcohol (25:24:1 saturated with 10 mM Tris, pH =
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8.0, 1 mM EDTA), mixed completely, and centrifuged for 5 min at 14,000 g. The aqueous layer solution was transferred into a new Eppendorf tube and precipitated with equal
volume of 100% isopropanol. The genomic DNA was recovered and dissolved with 10
mM Tris-HCl (pH = 8.0). The DNA samples were further sonicated into 500 bp with a
Misonix sonicator 3000 system. The concentration of sonicated DNA was determined by
Nano-Drop 1000 (Thermo Scientific). The sonicated genomic DNA was denatured in TE
buffer with 0.4 N NaOH at 100°C for 10 min, immediately chilled on ice for 10 min, and
spotted onto a positive-charged nylon transfer membrane (GE Healthcare) with a Bio-Dot
Apparatus (Bio-Rad). The membrane was baked for 30 min at 80°C and then blocked
with PBS containing 5% dry milk and 0.1% Triton X-100 for 1 h at room temperature.
Rabbit anti-5hmC antibody (1:10,000, Active Motif) was applied to the membrane and
incubated at 4°C overnight. In the next day, the membrane was rinsed with fresh PBS and
the colorimetric signal was developed after incubation with HRP-conjugated secondary
antibody for 30 min. The final signal was visualized with an ECL-Plus system (Amersham Pharmacia Biotech).

4.2.7

Immunohistochemistry for Tissue Slides

5 µm-thick tissue slices were sectioned from surgically resected, formalin-fixed paraffin-embedded tumors and mounted onto polylysine coated slides. Before staining, tissue slides were sequentially deparaffinized and rehydrated using xylene solution and ethanol series. Heat-induced epitope retrieval was carried out in boiling Tris-EDTA buffer
(pH = 9.0) for 20 min, followed by thorough wash with 0.025% Triton X-100 buffer.
Blocking was conducted in TBS buffer containing 10% goat serum and 1% BSA. The
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slides were then incubated with 1:200 diluted rabbit anti-MBD3 antibody (Pierce) or
1:500 diluted rabbit anti-5hmC antibody in a humid 4°C chamber overnight. After suppressing endogenous peroxidase with 0.3% H2O2, goat anti-rabbit IgG-HRP conjugates
(Life technologies) were applied for 1 h at room temperature. Color signal was developed
by using AEC staining Kit (Sigma) and then the slides were sealed in mounting medium
prior to optical imaging.

4.3
4.3.1

Results

Loss of MBD3 and Relevant Transcriptomic Changes in Gliomagenesis

A negative correlation between glioma grade and MBD3 expression was noted from
immunohistochemistry staining (Figure 4.1A-B). Considering that brain is the organ with
the highest level of 5hmC and it has been postulated as one of the major MBD3-binding
targets, the amount of 5hmC in the same batch of tumor tissues was thus examined. Evidently, 5hmC displayed a similar reduction pattern in high-grade gliomas (Figure 4.1C).
Moreover, in high-grade tumors, the intra-group variation of the MBD3 and 5hmC quantities becomes more significant.
After uncovering the serial loss of MBD3 in the aggravation of glioma grade, the altered gene expression related to MBD3 was profiled by RNA microarray. MBD3 siRNAs
were introduced into SF767 cells and the knockdown efficiency was confirmed by qRTPCR, western blot, and immunofluorescence (Figure 4.2A-B). Next, the genome-wide
changes in transcriptome were probed by the Agilent microarray (Figure 4.2C). In parallel, the DEGs between low-grade glioma and GBM tissues were screened for comparison.
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As shown in Figure 4.3 and Figure 4.4, a considerable overlap in the impacted protein functions between these two sets of DEGs is observed, which implicates that during
the progression from a low-grade to a high-grade glioma MBD3 is involved in a substantial number of gliomagenetic pathways and functions. For the down-regulated DEGs by
MBD3-KD, the top-matched gene ontology (GO) is the “MHC II protein complex”,
which is a surface protein complex presenting antigens to the CD4+ T cells. In analysis of
the up-regulated DEGs, the major differences between low-grade gliomas and GBM are
“nucleic acid binding proteins” and “transcription factors”, while depleting MBD3 further disturbs the expression of many “receptor proteins” (e.g., G-protein coupled receptors) in GBM cells. Other up-regulated DEGs by MBD3-KD include transport proteins
(e.g., ion channel proteins and solute carrier family), cytochrome P450 family, growth
factors (e.g., FGF and IGF), and dynein proteins, all of which are hallmarks of active cell
metabolism and proliferation. From another aspect, the MBD3-KD induced DEG-related
cell functions and diseases, as revealed by the Ingenuity Pathway Analysis (IPA), mainly
point to “gliomagenesis”, “inflammatory responses”, “metabolism”, “neural signaling”
and “neurological disorder” in the central nervous system (CNS) (Figure 4.5). Out of the
7,419 probed lncRNAs, about 600 are determined to be significantly altered upon MBD3KD, though the majority of their functions require future exploration due to the lack of a
well-defined annotation database. One interesting finding is that the lncRNAs regulated
by MBD3 is not fully consistent with the natural distribution on chromosomes. Instead, a
skewed distribution is observed. Chromosomes 2, 5, 6, 8, 13, and X encompass a higher
percentage of the MBD3-influenced lncRNAs than the expected number. Given the importance of lncRNAs to the chromatin integrity, transcription rate, and post-translational
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modification, this phenomenon preliminarily suggests that a dysfunction in MBD3 may
compromise more functions relating to those specific chromosomes.

Figure 4.1 Expression pattern of MBD3 in normal brain tissue and malignant glioma. (A)
Representative IHC images. Images were taken from an Olympus BX53 microscope fitted with a bright illumination and a 20× objective lens. (B) Semi-quantitative results from
the IHC images using the ImageJ software. (C) Quantity of 5hmC from the same groups
of patients by dot blot. ANOVA was performed for statistical analysis.
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Figure 4.2 Genome-wide transcriptome regulated by MBD3 in GBM cells. The knockdown efficiency by the MBD3-siRNA was validated by (A) qRT-PCR (up to 6 days), (B)
western blot and immunofluorescence staining (at day 4). (C) Upon the knockdown of
MBD3, the changes in transcriptome were quantified with Agilent one-color microarray.
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Figure 4.3 Protein classification and GO analysis for the down-regulated genes by
MBD3-KD. Differences between GBM and low-grade glioma are presented as the reference (dash line). The number of proteins appearing in both the DEGs is presented in the
pie chart. The top 5 matched GO terms mediated by MBD3 is presented in table.

Figure 4.4 Analysis for the up-regulated genes by MBD3-KD.
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Figure 4.5 Cellular functions and diseases related to the DEGs in MBD3-KD GBM cells
were profiled with the IPA software.
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4.3.2

Regulatory Function of MBD3 on MHC Class II Molecules

Since the down-regulation of MHC II protein complex was ranked top in GO analysis, the raw array data for each MHC II subunit were extracted (Figure 4.6A). MHC class
II protein complex is a heterodimer comprising α chain and β chain that are transcribed
from the HLA genes on chromosome 6. Five major HLA-encoding regions exist there:
HLA-DM, HLA-DO, HLA-DP, HLA-DQ, and HLA-DR. It has been demonstrated that
MHC class II molecules could be constitutively expressed in glioma cells and their levels
negatively associate with the tumor invasion and malignancy.142, 147, 148 As shown in Figure 4.6B, in comparison with low-grade glioma, GBM has a significantly lower transcription of almost every HLA gene. Upon the MBD3 knockdown, ten HLA variants experienced a further decrease. It was speculated that a possible mechanism accounting for this
MBD3-induced massive down-regulation was through the MHC class II transactivator
(CIITA) gene since it exhibited the same reduction trend from the array results. The transcription of CIITA is subjected to epigenetic inactivation, mainly by DNA methylation in
its promoter IV region.146,

147, 149

In Chapter 3, MBD3 (by extension the Mi-2/NuRD

complex) has been demonstrated to maintain a hypomethylated promoter for those genes
poised to a dynamic transition in expression. Herein, a global DNA hypermethylation
was noted in MBD3-KD GBM cells, again supporting its demethylation potential (Figure
4.7A). Using MSP, the methylation level of the CIITA promoter IV region was found to
rapidly increase by about 20% after 72 hours of MBD3 knockdown (Figure 4.7B), which
supports an epigenetic control on the CIITA gene by MBD3. Other than DNA methylation, the extensively dysfunctional lncRNAs on chromosome 6 after depletion of MBD3,
as aforementioned, might influence the expression of MHC class II molecules as well.
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Figure 4.6 MBD3 facilitates the basal expression of MHC class II molecules in glioma
cells. The raw signal readings for all the MHC II subunits are presented (left panel). For
genes having multiple probes in the array, their transcriptional levels were averaged. The
MBD3-regulated HLA genes in GBM and MBD3-KD GBM cells were compared to that
in low-grade glioma (right panel).

Figure 4.7 MBD3 regulates the expression of the CIITA gene through DNA methylation.
(A) Global hypomethylation induced by MBD3-KD was assessed by immunoassay (upper panel, n = 3) and immunofluorescence (lower panel). (B) Increase in the methylation
of the CIITA promoter IV region was validated by MSP.

4.3.3

Influence of MBD3 on the Oncogenic miR-17-92 Cluster

The miR-17-92 cluster is among the first characterized miRNAs underpinning a variety of molecular events to promote oncogenesis. From the polycistronic MIR17HG lo-
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cus, a precursor transcript (pri-miRNA) is transcribed and can yield six mature miRNAs:
miR-17 (further derive the mature miR-17-5p and passenger miR-17-3p), miR-18a, miR19a, miR-20a, miR-19b-1, and miR-92a-1.150 These miRNAs separately or collaboratively regulate a broad spectrum of genes including p21, Rb1, Bim, and Pten, thus controlling
the cell fate151, 152 (Figure 4.8A, upper panel). Mainly activated by Myc and E2F proteins,
the increased expression of miR-17-92 has been reported in a number of malignancies.153,
154

From the microarray results, the number of MIR17HG transcripts in GBM is signifi-

cantly higher than that in low-grade glioma (Figure 4.8A, lower panel). A recent research
has revealed that MBD3-NuRD was able to directly compete with c-Myc to repress its
transactivation potential.155 In line with this, the transcriptional level of MIR17HG was
expected to be further enhanced by MBD3-KD. Afterwards, the quantity of each mature
miRNA from MIR17HG was determined by qRT-PCR, which proved that the processing
for the pri-miRNA gave rise to a heterogeneous distribution of the final products (Figure
4.8B, left panel). Specifically, miR-17-3p, miR-18a, miR-19a, and miR-20a experienced
a substantial increase upon MBD3 knockdown (Figure 4.8B, right panel). As the miR-1792 products are closely related to cell proliferation and migration, in vitro and in vivo assays were performed to establish the connection between MBD3 and the glioma malignancy (Figure 4.9). Collectively, the obtained results support that a loss in MBD3 would
release the restraint on Myc and subsequently up-regulate the transcription from the miR17-92 cluster, leading to a more aggressive tumor growth.
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Figure 4.8 MBD3 fine-tunes the Myc-mediated transcription of MIR17HG. (A) The transcriptional regulation and downstream key targets of MIR17HG are illustrated (upper
level). The pri-miRNA levels in low-grade glioma, GBM, and MBD3-KD GBM were
probed by microarray. (B) Composition of the mature miRNAs from MIR17HG in GBM
and their level changes upon MBD3-KD were quantified by qRT-PCR (mean ± standard
deviation, n = 3).
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Figure 4.9 Influence of MBD3 on glioma migration and proliferation. (A) Migration assay was performed using GBM cells with and without MBD3-KD. (B) Proliferation rates
of GBM cells with and without MBD3 siRNA (n = 4, mean ± standard deviation). (C) In
vivo tumor formation assay was performed by injecting GBM cells into mouse brain. By
H&E staining, the MBD3-KD GBM cells show more pleomorphic and basophilic nuclei
(scale bars: 50 µm).

4.3.4

Clinical Implication of MBD3 Expression in Glioma Prognosis

Following the experiments at the molecular and cellular levels, it inspired further efforts to explore the possibility of using MBD3 as a potential prognostic biomarker due to
its control on the glioma migration and proliferation. To test this hypothesis, a pilot clinical cohort was designed and the enrolled glioma patients were strictly matched with their
demographic attributes, pathological characteristics, surgical outcomes, and adjuvant
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therapies. 5hmC has been discovered as the major DNA modification in association with
MBD3 and early efforts aimed to exploit the clinical implication of 5hmC in glioma have
been attempted.156-158 The reduction of 5hmC in high-grade glioma was indeed noted in
this study. It is extensively perceived that epigenetic modifications and their associated
proteins function in a cooperative manner. Since the DNA modification is not convenient
to be detected, it is rational to quantitate the relevant binding proteins as an alternative in
the clinics. In this regard, a subgroup of 14 patients bearing correlative levels of MBD3
and 5hmC were recruited. After a 60-month follow-up, MBD3 – as well as 5hmC – exhibited a positive correlation with the patients’ survival. The PFS of GBM patients who
received gross total resection in surgery and adjuvant therapies (i.e., radiation therapy and
temozolomide) was considerably proportional to the intra-tumor contents of MBD3 and
5hmC (Figure 4.10). From the MRI imaging, tumors with a relatively high abundance of
MBD3 and 5hmC showed a more confined growth whereas a low abundance of MBD3
and 5hmC was connected to a more aggressive, pre-multifocal growth pattern (Figure
4.11). The prognostic connection was also perceivable in the enrolled grade II-III patients
(Figure 4.12). The NCI Rembrandt data further support the positive correlation between
the expression of MBD3 and the glioma survival, though with a marginal significance of
difference (p-value = 0.03, Figure 4.13). Altogether, these clinical data establish the potential of MBD3 as a novel epigenetic marker to complement 5hmC in improvement on
the clinical management for malignant glioma.
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Figure 4.10 Dual-quantification of MBD3 and 5hmC exerts a promising prognostic power for GBM patients. 6 GBM patients with a correlative abundance of MBD3 and 5hmC
were followed up after surgery. (A) IHC staining for MBD3 protein and 5hmC. (B) qRTPCR for MBD3 mRNA. (C) Dot blot for 5hmC. (D) Survival outcomes of the patients.
PFS: progression-free survival; OS: overall survival.
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Figure 4.11 Brain MRI images of the GBM patients enrolled in the clinical cohort. Before
surgery, the tumor growth was examined by the T1 post-contrast MRI imaging. The premultifocal growth of MBD3-low GBM features a rapid tumor expansion, aggressive infiltration to surrounding normal tissue, and poor survival. In comparison, the spherical, rimenhancing MBD3-high GBM features a relatively mild growth, confined edge, and better
survival.

92

Figure 4.12 Survival outcomes of the enrolled grade II-III patients.
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Figure 4.13 Distinct clinical implications of MBD3 and MBD2 in the survival of glioma.
(retrieved from the NCI Rembrandt database https://caintegrator.nci.nih.gov/rembrandt)
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4.4

Discussion

Although malignant glioma is a prevalent form of primary brain tumor with devastating outcomes, research on the involvement of epigenetic mechanisms in gliomagenesis is
relatively sparse. Like other solid tumors, the progression of glioma is fueled by a plethora of epigenetic aberrations, while it is yet uncertain whether the reader proteins for DNA
methylation play a role in this pathology even if some preliminary efforts were attempted.46, 47 In contrast to other MBD proteins (e.g., MBD1, MBD2, and MeCP2), MBD3 in
mammalian cells exhibits an elusive and context-dependent interaction with DNA methylation.159 For example, MBD3 has long been thought to lose its 5mC-binding specificity;
however, the in vivo co-localization of MBD3 with 5mC and its oxidized derivatives have
been unambiguously detected in a series of studies.5, 105-107, 117 Furthermore, overexpression of MBD3 could induce a global DNA demethylation,42 again implying the exquisite
participation of MBD3 in the DNA methylation homeostasis. Other than being a DNAbinding protein, MBD3 also serves as a constitutional subunit of the Mi-2/NuRD complex that catalyzes histone deacetylation and nucleosome remodeling.160 MBD3-NuRD
has proven to be a key factor in inhibition of tumorigenesis and naïve pluripotency in the
recent reports.155, 161 In spite of some discrepant conclusions, the functional importance of
MBD3 to the CNS is evident, from pluripotency to development, from synaptic connectivity to lineage commitment.134,

162-164

Herein this study further uncovered a MBD3-

mediated anti-glioma network. Consistent with the previous research, the microarray results validate that MBD3 exerts an influence on both active and silenced genes in glioma.
Bioinformatics analysis and the following in vitro/in vivo tests support that a higher level
of MBD3 might herald a better survival outcome.
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The MBD3-mediated regulation on MHC class II molecules holds a medical significance because it provides us with new avenues to understand the immune escape of gliomagenesis and to compose targeted immunotherapies. In traditional neuroscience, human
brain was thought to be an organ with immunological privilege due to the blockade by
blood-brain barrier (BBB) and the absence of intracranial lymphatic structures,165 which
can facilitate brain tumors to evade immune surveillance. However, the integrity of BBB
in glioma is often sabotaged along with the tumor invasion and deficient vasculature, and
the expression of immunological molecules is found in a variety of glial cells, including
microglial cells, astrocytes, and even glioma cells. Those discoveries strongly imply an
anatomic connection between the CNS and immune system. The recent groundbreaking
findings of the glioma infiltrating lymphocytes and meningeal lymphatic vessels consolidate the participation of immune responses in restricting glioma malignancy.166, 167 Enhancing the recognition of tumor antigens has therefore been proposed to be a promising
therapy, and a peptide-based glioma vaccine has been successfully developed to activate
the MHC class II molecules-dependent CD4+ T cells.143 However, an extensive downregulation of MHC class II expression is a pathological characteristic for invading glioma
cells,142 and thus restoring the expression of MHC class II molecules constitutes the first
task to the effectiveness of immunotherapy. In the early attempts of anti-glioma immunotherapy, in situ delivery of interferon-gamma (IFN-γ) with viral vectors was applied to
reinforce the expression of MHC class II molecules in glioma cells and enhance the antitumor activity of T cells.168, 169 From this work, the expression of MHC class II molecules
was confirmed to be utterly low in GBM when compared with that in normal brain tissue
and low-grade gliomas. Intriguingly, through epigenetically regulating the CIITA gene
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and relevant lncRNAs on chromosome 6, MBD3 could reactivate the expression of MHC
class II molecules and may serve as a new therapeutic target to benefit patients from the
booming immunotherapies. It is anticipated that tumors bearing a high MBD3 abundance
would respond better to therapeutic vaccination and immune-checkpoint-blockade agents
(e.g., CTLA-4 and PD-1/PD-1L inhibitors). Furthermore, engineering the MBD3 expression by novel genome-editing tools also holds a great promise for future gene therapies.
Upon recognition of a 6-8 nucleotide “seed” region in target mRNAs to halt translation or trigger the mRNA degradation, miRNAs pose another layer of post-transcriptional
regulation in gene expression. A growing body of evidence has supported the involvement of miRNAs in each stage of oncogenesis. The miR-17-92 cluster, also dubbed “oncomiR-1”, gives birth to a group of miRNAs that control the cell proliferation, apoptosis,
and angiogenesis. Activation of the miR-17-92 cluster (i.e., the MIR17HG on C13orf25)
is mainly driven by two classes of transcription factors – the Myc and E2F proteins. In
malignant glioma, the copy-number amplification of MIR17HG is rare, indicating its upregulation primarily through the overactive Myc or E2F. The loss-of-control on the transactivation of miR-17-92 has been identified as a hallmark in hematopoietic malignancies
and solid tumors. For instance, overexpression of miR-17-92 was reported in neuroblastoma and correlated with a poor prognosis.170-172 Other miR-17-92-related cancers include lymphoma,173 leukemia,174 retinoblastoma,175 medulloblastoma,176 colorectal cancer,177 breast cancer178 and so on. In this study, the up-regulation of miR-17-92 in GBM,
in comparison to low-grade glioma, can be primarily attributed to the significantly higher
expression of n-Myc (up by 4.46-fold) and E2Fs (e.g., E2F1 up by 7.77-fold and E2F2 up
by 16.04-fold). In function, MBD3 is able to epigenetically suppress the transactivation
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potential of Myc proteins. This explains the secondary increase of the MIR17HG transcripts when MBD3 was depleted in GBM cells.
Encouragingly, MBD3 can complement 5hmC to bring about a remarkable value to
predict the glioma survival. This positive correlation inspires a mechanistic exploration.
Catalyzed by the TET family enzymes, 5hmC is the first oxidized derivative of 5mC. The
content of 5hmC is heterogeneous among different tissues but is most enriched in the
CNS (0.3-0.7% of the whole genome).179, 180 5hmC locates in the midst of the DNA demethylation pathway, hence critical for the dynamic gene activation. Besides being a demethylation intermediate, 5hmC has further proven to be a predominantly stable DNA
modification that regulates a plethora of biological functions through interactions with
various partners. MBD3 is one of the few identified factors exhibiting appreciable in vivo
association with 5hmC, though some recent studies failed to validate the specific in vitro
MBD3-5hmC interaction. Considering the organ-dependent and dynamic nature of epigenetic modifications as well as their extensive cooperation in the regulatory network, the
connection between MBD3 and 5hmC in the CNS ought to be substantive because such
an enriched cytosine modification (i.e., 5hmC) has to be interpreted by appropriate readers. Interestingly, the enrichment of MBD3 or the 5mC-binding protein MBD2 indicates
opposite prognosis in the glioma survival even though their sequences are highly similar
(Figure 4.13). This intra-MBD family divergence highlights the epigenetic intricacy and
indirectly signifies a MBD3-MBD2 counteraction in the DNA methylation homeostasis
as discovered in Chapter 3. The clinical implication about 5hmC reduction in a couple of
cancers, including malignant glioma, has been preliminarily established. This study incorporates one of the major 5hmC-associated factors to bolster the reliability of using ep-
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igenetic markers to predict the survival of glioma patients, as well as provides an alternative epigenetic marker easier to be characterized in clinical samples. In long term, it is
expected that the obtained information will provide new insights to clinical management
of individual patients and epidemiological reference for large-scale studies.
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CHAPTER 5. A PLGA-PEG NANO-DELIVERY SYSTEM FOR EPIGENETIC DNA
DEMETHYLATING THERAPY

5.1

Introduction

Epigenetic aberration has the potential to reshape cellular functions and is appreciably involved in oncogenic processes. Significantly, epigenetic silencing of tumor suppressor genes is one of the major causes for tumor progression and drug resistance.181, 182
However, in contrast to genetic mutations, the cancerous epigenetic errors can be reversed through chemotherapy with relative ease and less side effects because epigenetic
modifications do not need to change the DNA sequence of a gene. This feature makes
epigenetic therapy a promising intervention strategy.183, 184 The essential goal of epigenetic therapy is to target the diseased chromatin in rapidly dividing tumor cells and return it
to a phenotypic “normal state” while only mildly disturbs the epigenome in healthy cells.
The most widely studied epigenetic modification in human cancers is DNA methylation. This modification is one of the prevailing marks for controlling gene expression,
genomic stability, chromatin integrity, and cell fate.185, 186 Regions with dense CpG dinucleotides, namely CpG islands, are predominantly found at gene promoters and usually
free of methylation in normal cells. The idea of therapeutically inhibiting DNA methylation emerged from studies showing that a plethora of genes (mainly tumor suppressor
genes and apoptosis-related genes) boast a gain-of-methylation (hypermethylation) dur-
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ing tumorigenesis.187, 188 This process is associated with an epigenetic inactivation of the
gene expression and thus loss of the protein functions, which leads to the revival of interest in drugs discovered decades ago being potent inhibitors of DNA methyltransferases
(DNMTs) to restore relevant anti-tumor activities in malignant cells.57, 189
Two commercially available agents targeting DNA methylation – AZA and DAC –
are now alternative options for treatment of myelodysplastic syndrome.190, 191 As cytidine
analogues, AZA and DAC exert their effect by incorporating into replicating DNA and
inhibiting DNMTs by forming covalent adducts in fast-dividing cells. With more DNMTs
entrapped, DNA methylation is incrementally reduced along cell proliferation. Eventually,
demethylation at tumor suppressor genes is achieved in daughter cancer cells, but only
minimally affects resting or non-dividing cells.192
A growing body of evidence (from preclinical tests and clinical trials) suggests that
the DNA demethylating drugs might induce an anti-cancer response in solid tumors.193-196
However, extending the therapeutic effects of DNA demethylating agents to in vivo solid
tumors still faces substantial hurdles due to the difficulties in drug delivery and cellular
uptake.189 In order to attenuate abnormalities of DNA methylation in cancer cells, several
aspects of the current drug formulation need to be carefully improved: aqueous stability,
in vivo bioavailability, transmembrane efficiency, resistance to efflux, side effects, and
long-term efficacy.197 Among the challenges, effective delivery of the DNA demethylating drugs is perhaps the most significant barrier for expanding the therapeutic indications
from blood malignancies to solid tumors.
Efficient accumulation of cytidine analogues in cells relies on the presence of particular membrane nucleoside transport proteins such as the hCNT proteins.198-200 The ATP-
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dependent cellular internalization and short half-life of the DNA demethylating drugs in
physiological liquids would compromise the expected therapeutic activities against solid
tumors. AZA and DAC are subjected to a series of physicochemical attacks when administered to human body, mainly including degradation by hydrolysis, deformation of the
triazine ring, and anomerization of the ribose ring under neutral-to-basic conditions.201, 202
One strategy to overcome the pharmacological challenges in drug delivery is to modify the drug structures. However, a considerable number of those modifications could inevitably diminish the therapeutic efficacy and cause unwanted toxicity. A variety of AZA
derivatives have been developed, yet with decreased performance compared to the parental drug. Just to name a few here: 5-fluoro-2'-deoxycytidine is highly toxic;203, 204 1-(β-Dribofuranosyl)-1,2-dihydropyrimidin-2-one is less potent;205 5,6-dihydro-5-azacytidine
has a poor incorporation ability;206, 207 2'-deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5azacytidine (NPEOC-DAC) severely impacts liver function;208 and some drugs require
pre-activation by certain enzymes: CP-4200 by plasma membrane lipases,209 S110 by cellular phosphodiesterases,210 and NPEOC-DAC by carboxylesterase.207, 208
Another strategy is to compose a nanoscale delivery system that has the potential to
improve the therapeutic efficacy of demethylating drugs. An ideal delivery vector should
protect drugs from premature hydrolysis in blood circulation, increase bioavailability, and
enhance cellular internalization. With controlled fabrication, nano-carriers could facilitate
the in situ retention of demethylating agents, extend the exposure of cancerous tissue to
an efficacious drug concentration, and minimize the re-methylation of tumor-suppressor
genes until an irreversible elimination of tumor cells. In this regard, the nanomaterialprotected drug molecules become more effective than parental compounds in treating sol-
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id tumors.211, 212 Till today only a handful of nano-vectors have been developed to deliver
epigenetic chemo-payloads to solid tumors, but none of the past work has demonstrated
the potential of a poly(lactic-co-glycolic acid) (PLGA)-based system for delivery of the
DNA demethylating drugs.
Use of the biodegradable PLGA as the drug delivery system has been well defined,
while most of the applications were demonstrated to physically encapsulate the drug molecules. However, this formulation is sensitive to various environmental factors that could
result in an undesired burst release.213, 214 Instead, chemical conjugation of a drug with
the backbone of PLGA would greatly enhance the drug stability and also facilitate a pHdependent release. Hence, in this work the aliphatic polyester PLGA is combined with
the hydrophilic polyethylene glycol (PEG) to produce an A-B type of di-block copolymer
for conjugation with AZA or DAC (Figure 5.1). Under an equimolar drug concentration,
the nano-conjugate form of drug experiences a rapid endocytosis and can better reactivate
the apoptotic pathway to inhibit cell proliferation. In light of this improved cell uptake, a
low concentration of DAC-PLGA-PEG was applied to sensitize the alkylation-resistant
glioblastoma cells to temozolomide. These polymers are able to diffuse through loosely
packed endothelial cell junctions of blood capillaries in the vicinity of tumor tissue and
enrich in tumor cells due to the “enhanced permeation and retention” (EPR) effect. With
prolonged circulation and bioavailability, AZA-PLGA-PEG gains a more potent in vivo
efficacy over free AZA in treating xenografted breast cancers. Notably, the active glycolysis in cancer cells often generates an acidic microenvironment in which the PLGA-PEGbased nano-vector could release the conjugated drug molecules at a faster rate than in
normal cells. This unique property substantially avoids an excessive damage to normal
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cells. Taken together, this chapter describes a novel delivery strategy for DNA demethylating agents and provides a cost-effective formula for future pharmaceutical applications.

Figure 5.1 Design of the nano-conjugate and principle of delivery.

5.2
5.2.1

Methods and Materials

Synthesis of PLGA-PEG-OCH3 (Conjugate 1)

The PLGA-PEG di-block was synthesized as described in previous studies with minor modifications.215 PLGA 50:50 with an average molecular weight 8,586 Da (0.31 mM)
was dissolved in dry dichloromethane (DCM, 10 mL). The carboxylic acid group in
PLGA was first activated by N,N'-dicyclohexylcarbodiimide (DCC, 0.375 mM) and Nhydroxysuccinimide (NHS, 0.62 mM) at room temperature overnight. The side product
dicyclohexylurea (DCU) was filtered out; the obtained PLGA-NHS was precipitated by
ice cold diethyl ether (Et2O) and dried under vacuum. The activated PLGA (2 g) was then
added into methoxy polyethylene glycol (H2N-PEG-OCH3) (molecular weight = 750 Da,
0.42 mM) solution in 10 mL dry DCM, and the reaction mixture was stirred at room tem-
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perature for 24 h. The PLGA-PEG conjugate was precipitated out from the reaction mixture by adding Et2O and centrifuged at 3,220 g for 10 min. The supernatant was discarded
and the polymer was washed with a mixture of Et2O and hexane 50:50 (3 × 5 mL) to remove excess reagents. Finally, the polymer was dried under vacuum for 24 h to obtain
the conjugated product (yield = 92.83%). The coupling efficiency was determined by 1H
NMR spectroscopy: ~99.2% of PLGA was conjugated with PEG.

5.2.2

Activation of PLGA-PEG-OCH3 by Succinic Anhydride (Conjugate 2)

The PLGA block of Conjugate 1 was modified by reacting with succinic anhydride
to produce HOOC-PLGA-PEG. 1.78 g of Conjugate 1 was dissolved in dry DCM (10 mL)
containing 4-dimethylaminopyridine (DMAP 25% w/v) as a catalyst, and succinic anhydride (39.3 mg) was added. After stirring at 50°C overnight, the DCM was removed in
vacuum. This Conjugate 2 was re-dissolve in dry DCM and precipitated in ice cold Et2O,
dialyzed against water for 4 h using MWCO 3,500 and lyophilized (yield = 81%). The
polymer was characterized by 1H NMR (400 MHz): δ (ppm) = 5.36–5.00 (m, PLGACH2-), 4.94–4.57 (m, PLGA-CH2-), 3.67–3.58 (m, PEG-CH2-), 3.38 (s, PEG-OCH3),
1.52 (s, PLGA-CH3). The percentage of modification was determined to be 97.2%.

5.2.3

Synthesis of AZA/DAC-PLGA-PEG (Conjugate 3)

Conjugate 2 (0.08 mM) was dissolved in dry DCM containing 4-(dimethylamino)
pyridinium-4-toluene sulfonate (DPTS, 0.23 mM) and cooled at 0°C. For the reaction
mixture, AZA or DAC (0.09 mM) dissolved in dry N,N-dimethylformamide (DMF) was
added with continuous stirring. Then 0.23 mM DCC in pyridine was added slowly to the
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solution and the reaction was carried out at 4°C for 72 h under N2. The progress of reaction was monitored by TLC with CHCl3/CH3OH (1:4, v/v) as eluent (product retention
factor: RfAZA = 0.56, RfDAC = 0.68). The DCM and pyridine were removed under reduced
pressure and the product was re-dissolved in DCM and precipitated in ice cold Et2O. Untreated drug and other impurities were removed followed by dialysis. The dialyzed solution was precipitated in ice cold Et2O/hexane (50:50) mixture, freeze-dried and kept at 20°C. The drug conjugate was characterized by UV and 1H NMR spectroscopy. 1H NMR
of AZA-PLGA-PEG (400 MHz): δ (ppm) = 8.56 (s, 1H, H-6), 7.49-4.53 (bs, 2H, NH2),
5.76 (s, SA-O-CH2), 5.65-5.64 (d, 1H, H-1ˈ, J = 4), 5.40-5.41 (bs, 1H, OH-2ˈ), 5.25-5.14
(m, PLGA-CH2-),5.03-4.99 (m, 2H, H-4ˈ and OH-3ˈ), 4.91-4.83 (m, PLGA-CH2-), 3.99
(m, 1H, H-3ˈ), 3.84-3.81 (m, 1H, H-2ˈ), 3.67–3.59 (m, 2H, H-5ˈ; H-5ˈˈ), 3.49 (m, PEGCH2-), 3.22 (s, PEG-OCH3), 1.46 (s, PLGA-CH3). 1H NMR of DAC-PLGA-PEG (400
MHz): δ (ppm) = 8.56 (s, 1H, H-6), 7.52-7.49 (s, 2H, NH2), 6.15 (t, 1H), 5.26 (s, SA-OCH2), 5.25 (m, PLGA-CH2-), 4.91-4.83 (m, PLGA-CH2-), 4.2 (s, 1H, H), 3.76 (1H, H),
3.6–3.7 (m, 1H, H), 3.7–3.5 (m, 2H, H), 3.49 (m, PEG-CH2-), 3.22 (s, PEG-OCH3), 1.46
(s, PLGA-CH3). The coupling efficiency revealed that over 90% of the carboxyl ends of
PLGA were conjugated with AZA.

5.2.4

Synthesis of PLGA-PEG-FITC (Conjugate 4)

The di-block polymer PLGA-PEG-NH2 (600 mg) was prepared as discussed above
and dissolved in 20 mL DCM. FITC (22.3 mg) was dissolved in 250 µL of a mixture of
DCM/pyridine and added to the copolymer solution. The reaction was stirred at 4˚C for
24 h in dark. The resultant conjugate was precipitated by ice cold Et2O (125 mL). The
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polymer was centrifuged at 3,220 g for 30 min. The supernatant was discarded and the
polymer was washed thoroughly by Et2O (5 mL × 3) and dried under vacuum overnight.
The yield of FITC conjugation was determined using fluorescence spectrometry at an excitation wavelength of 485 and emission at 530 nm.

5.2.5

Preparation and Characterization of Nano-Micelles

Due to the amphipathic property of PLGA-PEG, it would form nano-micelles in solution and the drug molecules are protected in the core. Non-fluorescent (only drugcontaining conjugate) and fluorescent (drug-containing conjugate : FITC-containing conjugate = 2 : 1) nano-micelles were prepared by film dispersion method.216, 217 A proper
amount of compounds was dissolved in chloroform at room temperature. The solvent was
then removed under reduced pressure to form a dry polymer film. This film was hydrated
with 10 mM HEPES buffer (pH = 7.4) at room temperature for 30 min. The nanomicelles were extruded through a 200 nm polycarbonate membrane. The yield of products was determined by UV-Vis spectroscope for non-fluorescent nano-micelles and fluorimeter for fluorescent nano-micelles.
During synthesis, gel permeation chromatography (GPC) was performed to monitor
each conjugation using an Agilent 1200 series Wyatt Dawn Heleos-II system equipped
with a UV, LSD & RID detector. DMF was used as the mobile phase at a flow rate of 0.3
mL/min through OHpak SB-803 HQ column [8.0 × 300 (mm): inner diameter × length]
at 40°C. GPC calibration was constructed using polystyrene standards. The size and morphology of nano-micelles were determined by transmission electron microscope (TEM,
Philips, CM1000) with the acceleration voltage of 100 kV. Samples were diluted to 0.5
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mg/mL with HEPES buffer and stained with 0.8% uranyl acetate. The surface charge of
nano-micelles was measured with a ZetaPlus analyzer (Brookhaven).

5.2.6

Uptake and Release Assays

The uptake and intracellular release of fluorescent nano-micelles were characterized
by confocal imaging, FCS, PCH, and FLIM. The pH-dependent drug release kinetics was
evaluated with a UV-Vis method. AZA/DAC-PLGA-PEG nano-conjugate was suspended
in 500 µL PBS (pH = 5 or 7.4) and dialyzed (MWCO 3,000 Da) against 1.5 mL medium.
Then the tubes were placed in an orbital shaker setting at 120 rpm and 37°C. At predetermined time points (1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h), a 10 µL aliquot was withdrawn
and replaced with fresh buffer. The released AZA or DAC concentration was quantified
at a characteristic wavelength: AZA – λmax 254 nm (pH 5) and 223 nm (pH 7.4); DAC –
λmax 244 nm (pH 5) and 220 nm (pH 7.4).218 The calibration curve for drug quantity was
linear over the concentration range from 100 to 4000 ng/mL.

5.2.7

In vitro Therapeutic Tests of DAC-PLGA-PEG against Glioblastoma

Human SF767 and U87 GBM cells were cultured in IMDM medium supplemented
with 10% fetal bovine serum, 1% antibiotics, and 1% glutamate. MTT assay was used to
test the short-term cell viability after DAC-PLGA-PEG and temozolomide treatment. In a
96-well plate, 3,000 cells were seeded in each well to grow for 24 h, followed by incubation with appropriate drugs. After 72 h, the culture medium was quickly removed and the
cells were rinsed with clean 1 × PBS. The cells were then incubated with 100 mL fresh
medium containing 10 mL thiazolyl blue tetrazolium bromide solution (MTT, 5 mg/mL
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in PBS as stock) for 3-4 h and the formed formazan was dissolved with 150 mL acidic
isopropanol prior to measurement by a microplate reader at the absorbance of 570 nm.
For long-term proliferation assay, 5,000 cells were seeded to a T25 flask at day 0, and the
cell number under each specific condition was recorded for 8 days. During the long-term
treatment, the global DNA methylation was quantified with colorimetric immunoassay at
day 4 and day 8, respectively. In addition, four apoptosis-related genes (p53, p21, Caspase3, and BRCA1 by qRT-PCR) and cell cycle progression (flow cytometry) were evaluated upon different treatments.
Table 5.1 PCR primers used in Chapter 5
GAPDH
p53
p21
Caspase3
BRCA1

5.2.8

(F)CAGCCTCAAGATCATCAGCA
(R)TGTGGTCATGAGTCCTTCCA
(F)CCCCTCCTGGCCCCTGTCATCTTC
(R)GCAGCGCCTCACAACCTCCGTCAT
(F)GAGGCCGGGATGAGTTGGGAGGAG
(R)CAGCCGGCGTTTGGAGTGGTAGAA
(F)ATGATGACATGGCGTGTCATAA
(R)AAGGAAAAGGACTCAAATTCTGTTG
(F)CAAGGAACCAGGGATGAAATCAG
(R)ATGGCTCCACATGCAAGTTTG

In vivo Therapeutic Tests of AZA-PLGA-PEG against Breast Cancer

After testing the in vitro cytotoxicity of AZA-PLGA-PEG by MTT assay, the in vivo
anti-tumor potential was assessed. Female nude mice (18-25 g in body weight) were subcutaneously implanted with 5 × 106 MCF7 cells. Following xenografting, tumors were
allowed to grow for another 21 days until reached 190-200 mm3. Mice were sorted randomly into three groups: control, free AZA treatment, and AZA-PLGA-PEG treatment. A
total of 16 doses of PBS saline, free AZA (1 mg/kg), or AZA-PLGA-PEG conjugate
(with equivalent AZA content of 1 mg/kg, micelle concentration = 1.53 mg/mL) were
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administered via intraperitoneal (IP) injection to each group in four weeks (two cycles of
eight consecutive doses). Tumor volume was measured twice a week with an electronic
caliper (v = 0.5 × L × W2 mm3) and the body weight of mice was monitored in parallel.
All animal handling followed the guidelines of the Purdue Animal Care and Use Committee and approved by the Purdue Center for Cancer Research.

5.2.9

Statistical Analysis

In significance test: Student’s t-test (two-tail) was used for two sample comparison,
and ANOVA was used for multiple sample comparison. All the analyses were performed
with the OriginPro software. Without specific note, all data are presented with mean and
standard deviation.

5.3
5.3.1

Results and Discussion

Synthesis and Characterization

Cytidine analogues are highly unstable in aqueous condition, which greatly restricts
their experimental and clinical applicability. This instability is due to the rapid hydrolysis
and opening of the heterocyclic nitrogen ring caused by nucleophilic attacks at the N-5
position. The formed N-(formylamidino)-N-β-d-ribofuranosylurea intermediate would be
then slowly converted into 1-β-d-ribofuranosyl-3-guanylurea.202 This destructive decomposition hinders efficient drug conjugation and storage. New experimental methodologies
are thus needed for more effective particle formulation and drug delivery.
Two methods have been developed for incorporation of drug into nano-vectors. The
most widely used is physical entrapment, which is quite simple as no chemical modifica-
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tion is required. However, burst release is a grand shortcoming due to a premature loss of
the physically loaded drug before reaching the target site. The second method is chemical
conjugation in which the drug molecules are covalently bonded to nano-vectors and then
undergo a controlled release since additional mechanisms are usually needed to trigger
the pharmacological action. This strategy has not been widely adopted mainly because of
the limited number of reactive sites available on a nano-vector and few conjugation reactions that would not impact the raw compounds. For instance, even a tiny chemical linker
could drastically change the structure and therapeutic value of a chemotherapeutic drug.
In this study the drug-containing nano-conjugate was prepared with a three-step synthetic route (Figure 5.2A). First, NHS-activated PLGA reacted with PEG to form the copolymer PLGA-PEG. Then the terminal hydroxyl group of PLGA-PEG was converted to
carboxylic group by reaction with succinic acid, and the succinylated PLGA-PEG copolymer was allowed to react with the 5’-OH of AZA or DAC in the presence of DCC and
DPTS, to result in the formation of AZA/DAC-PLGA-PEG conjugate. Products were isolated and purified by precipitation and dialysis, followed by characterization with GPC
(Figure 5.2B), TEM (Figure 5.2C), and 1H NMR (illustration with AZA-PLGA-PEG in
Figures 5.3-5.5). The drug content was determined to be 25 µg/mg for AZA-PLGA-PEG
and 22.9 µg/mg for DAC-PLGA-PEG. The formed nano-micelles in solution are spherical in shape with an average size of about 50 nm. The surface charge was found to be
nearly neutral by zeta-potential (Table 5.2). The physicochemical characteristics of polymeric nanoparticles including size, shape, and surface charge are critical factors for their
stability, in vivo pharmacokinetics and bioavailability. In human body, exogenous molecules have to evade the reticuloendothelial system (RES) which can otherwise opsonize
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the “invader molecules” and subsequently induce a degradation or phagocytosis by macrophages.219 PLGA-nanoparticles below 100 nm with a hydrophilic surface modification
such as PEG can minimize opsonization and clearance by the RES, which would prolong
the circulation time and allow more drug delivered to tumor lesions.220 Another rationale
for PEGylation aims to solve the problem that positive-charged particles easily bind to a
variety of cells in the body, such as vascular endothelial cells, before reaching the target
loci. Hence, it is favorable to maintain a nano-vector as either neutral or slightly anionic
for stabilization and preventing non-specific drug loss.221, 222

Figure 5.2 Synthesis of AZA/DAC-PLGA-PEG nano-conjugate. (A) Steps for chemical
conjugation. (B) Successful conjugation for each component was validated by decreased
retention time in GPC. (C) TEM image of the formed nano-micelles.
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Figure 5.3 1H NMR spectra and the corresponding peak assignments for AZA.
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Figure 5.4 1H NMR spectra and the corresponding peak assignments for activated PLGAPEG.
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Figure 5.5 1H NMR spectra and the corresponding peak assignments for AZA-PLGAPEG.

Table 5.2 Basic characteristics of the nano-micelles with different compositions
Nano-micelle Composition

Particle Size (nm)

Surface Charge (mV)

AZA-PLGA-PEG

45 ± 5.2

-0.87 ± 2.1

DAC-PLGA-PEG

55 ± 6.4

-0.99 ± 1.5

PLGA-PEG-FITC

59 ± 3.4

-1.10 ± 2.3

5.3.2

Uptake and Release Kinetics

To track the drug uptake and release kinetics, fluorescent nano-micelles were incubated with cells for up to 6 hours. From the time-lapse confocal imaging, it can be seen
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that the cross-membrane diffusion rapidly completed within 2 hours (Figure 5.6A). Next,
a more quantitative exploration with single-molecule fluorescence tools was performed
(Figure 5.6B). By mixing 50 nM drug-containing conjugate and 25 nM FITC-containing
conjugate, the original concentration of the nano-micelle solution was determined to be
13.8 nM in FCS calculation. The intracellular concentration of nano-micelles could reach
83.5 ± 5.0 nM within the first hour of incubation, validating the high uptake efficiency of
this PLGA-PEG-based nano-vector. After 4 hours, the intracellular concentration peaked
at 145.8 ± 13.4 nM as shown in Figure 5.6B. Notably, the diffusion coefficient of nanomicelles in living cells did not experience drastic changes within the detection window
(Figure 5.6B, inset), which indicates that no significant aggregation or abrupt particle disintegration occurred in 6 hours. From PCH, the average brightness of nano-micelles displayed a gradual increase (Figure 5.6C). It gives rise to a speculation that some PLGAPEG fragments with FITC tags hydrolyzed from early taken nano-micelles would integrate into newly internalized micelles due to physical adsorption or hydrophobic force. In
the fluorescence images, a uniform distribution of nano-micelles over the entire cell was
noted without a significant compartmental entrapment, implying an endo-lysosomal elusion (Figure 5.6D). The results from FCS and PCH together suggest that the maximum
uptake of the PLGA-PEG nano-micelles could occur within 1 hour (Figure 5.6C, black
dash line), followed by an accelerated hydrolysis process (Figure 5.6C, red dash line).
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Figure 5.6 Uptake and distribution of PLGA-PEG nano-micelles. (A) Confocal imaging
of cells incubated with fluorescent nano-micelles. (B) Autocorrelation functions from live
cells were fitted with a 3D diffusion model to obtain the diffusion coefficient (inset) and
concentration of internalized nano-micelles. (C) Summary of the average concentration
and brightness of nano-micelles in cancer cells (n > 20 cells, mean + S.E.M.). (D) Escape
of nano-micelles from the endo-lysosomal system.

To verify the pH-dependent PLGA hydrolysis, in vitro drug release assay was performed in acidic and neutral environments. As shown in Figure 5.7B, the hydrolysis rate
was significantly faster at an acidic pH than in a neutral environment. Approximately 85%
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of the conjugated drug was released at pH 5.0 within the first 12 hours, whereas only ~40%
was released at pH 7.4. This supports the susceptibility of the ester bond-based PLGAPEG conjugate to acid; however, a more comprehensive investigation is required for future in vivo applications due to the lack of analytical methods to distinguish the intact
AZA/DAC from the degraded intermediates.192, 223 Moreover, the hydrolysable chemical
links within the conjugate render the rate of drug release a near zero-order kinetics under
physiological pH, which provides additional benefits for in vivo usage.

Figure 5.7 pH-dependent drug release from PLGA-PEG nano-micelles. (A) UV-Vis spectra of cytidine analogue and the PLGA-PEG copolymer below 300 nm. (B) In vitro drug
release kinetics in acidic or neutral environment (n = 3).

In cancer cells with a relative acidity caused by the Warburg effect, upon the hydrolysis of PLGA a fast accumulation of lactic acid and glycolic acid was expected, and these
two products would further acidify the intracellular environment to facilitate a drug release cascade. To some extent, the acidifying pH could not only advance the PLGA hydrolysis but also slow down the triazine ring-opening decomposition of the drugs,218 thus
conferring a better efficacy against cancer cells. Since a reduced fluorescence lifetime of
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FITC is a sensitive measure of low pH, FLIM was used to assess the PLGA hydrolysisrelated acidification in living cells. Figure 5.8A shows the time-course FLIM images at
different incubation times. It is evident to see that along the incubation the fluorescence
lifetime of FITC was continuously shortening, which can also be perceived from the shift
in the lifetime histograms (Figure 5.8B). Taken together, the intracellular behavioral
mode for PLGA-PEG nano-micelles was proposed (Figure 5.9). Having a size of 50-60
nm, the formed nano-micelles can rapidly enrich in cancer cells within 1-2 hours and the
delivery of AZA/DAC here, to a great extent, is thus independent of nucleoside transporters. Instead, the trend of an initial linear increase and a later saturation stage as revealed by FCS, strongly suggest that the cell internalization of sub-100 nm PLGA-PEG
nanoparticles is the outcome of a cooperation between fluid-phase pinocytosis and clathrin-mediated endocytosis,224 in contrast to the mechanism for large-sized nanoparticles
(e.g., via extracellular release of the drug payload to contacting cells).225 The rapid endolysosomal escape is another advantage for the PLGA-PEG-based delivery since a further
anionic-to-cationic reversal of the surface charge facilitates the nanoparticle to interact
with the endo-lysosomal membrane and achieve the escape in 10 minutes.226 Afterwards,
the internalized nano-micelles begin to be hydrolyzed and are sensitive to acidic pH in
cancer cells.
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Figure 5.8 PLGA hydrolysis-induced acidification inside cells. (A) FLIM images collected from the FITC channel. (B) Lifetime histograms of the internalized FITC at different
time points.

Figure 5.9 Single-molecule behavior of PLGA-PEG-based nano-micelles in cancer cells.
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5.3.3

DAC-PLGA-PEG Sensitizes Glioblastoma Cells to Temozolomide

Arising from normal glial cells, glioblastoma (GBM) constitutes the most prevalent
primary brain tumor in adults. Even with gross total resection in surgery and adjuvant
therapy, the median survival for GBM patients is only 14.6 months and the two-year survival is approximately 30%. As the frontline chemotherapy for GBM, temozolomide is
able to elicit a radical anti-tumor effect via inducing alkylation at the guanine residues in
DNA. However, after a temporary remission GBM would virulently relapse and become
chemo-resistant due to its infiltrating growth and rapid evolution to overcome selection
pressure. It has been recently demonstrated that pretreating the chemo-resistant GBM
cells with DAC could considerably sensitize GBM cells to temozolomide.227 In light of
this finding, it will be of tremendous value to improve the pharmacodynamics of DAC to
further its application in GBM.
First, two GBM cell lines with distinct responses to temozolomide were confirmed
by MTT assay. Cells were treated with temozolomide at a concentration of up to 30 µM
for 72 hours. From the results, U87 cells exhibited full response to temozolomide treatment and a dosage of 30 µM could suppress the cell proliferation by 90% (IC50 was estimated to be ~20 µM). In contrast, SF767 cells did not show any significant response to
30 µM temozolomide (Figure 5.10A). In the subsequent experiments testing combination
therapy, SF767 cells were first sensitized with DAC or DAC-PLGA-PEG with equivalent
drug content (50 nM) for 24 hours, followed by treatment with 30 µM temozolomide for
another 48 hours. When given separately, both DAC and DAC-PLGA-PEG showed certain cytotoxicity because of the non-specific effect, but the nano-conjugate form of drug
was more effective than the free drug due to the improved delivery efficiency. For cells
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pretreated with DAC or DAC-PLGA-PEG, 30 µM temozolomide could successfully suppress the proliferation rate by 47% and 62%, respectively (Figure 5.10B). This set of experiments thereby proves the synergistic effect between DAC/DAC-PLGA-PEG and temozolomide.

Figure 5.10 Therapeutic potential of combination treatments against GBM cells. (A) Distinct responses to temozolomide in U87 and SF767 cells. (B) Synergistic effects between
temozolomide and DAC or DAC-PLGA-PEG were tested in SF767 cells (n = 6).
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A critical pitfall for conventional PLGA-based delivery comes from its premature
burst release.228, 229 To solve this problem, the design of this study opted to chemically
conjugate DAC to the PLGA backbone instead of physically load the drug. This formulation merits a sustainable and controlled release. Hence, a better long-term efficacy from a
combinatorial therapy was expected. As presented in Figure 5.11A, the proliferation rate
of SF767 cells under a combination treatment using DAC-PLGA-PEG and temozolomide
is significantly lower (by ~70%) than that with DAC and temozolomide in 8 days. It was
also noted that a larger extent of DNA demethylation could be achieved by DAC-PLGAPEG than free DAC (Figure 5.11B), validating a more effective epigenetic remodeling.
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Figure 5.11 Long-term effects of the combination therapy. (A) The proliferation profiles
of SF767 cells under combination treatments (n = 3). (B) The global changes in DNA
methylation were monitored during the whole process (n = 3).

Since both DAC and temozolomide function by alkylating DNA yet on different nucleotides, the next query is to test whether their synergistic effect stems from triggering a
more intense response to DNA damages. Quantitative RT-PCR was thus applied to check
four key genes relating to DNA damage and apoptosis: p53, p21, Caspase3, and BRCA1.
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Consistent with the cytotoxicity assays, 30 µM temozolomide alone did not evoke any
significant changes in the transcription of these genes in SF767 cells, whereas the combination treatment (DAC-PLGA-PEG and temozolomide) radically reactivated p53 and p21
(Figure 5.12A). On the contrary, Caspase3 and BRCA1 were not influenced, verifying a
DAC-induced, Caspase-independent apoptosis and the impaired BRCA1 function in glioma cells.230, 231 The elevation of p53 and p21 could in turn halt the cell cycle progression
at the checkpoints. Examined by flow cytometry, a much larger proportion of cells were
found to be arrested in the G2/M-boundary when the combination treatment was administered (Figure 5.12B), which is in agreement with the previous research on DAC pharmacology.232, 233 Collectively, these data suggest that one major mechanism for DAC to potentiate temozolomide in GBM cells hinges on better eliciting the DNA damage-induced
proliferation retardation, though it cannot rule out that the observed increase in p53 and
p21 might also be attributed to the induced demethylation at their promoters.
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Figure 5.12 DAC-PLGA-PEG nano-conjugate better sensitizes the chemo-resistant GBM
cells to temozolomide. (A) Transcriptional levels of four DNA damage-responsive genes
were quantified by qRT-PCR after 72 hours of treatment (n = 4). (B) Cell cycle progression was evaluated by flow cytometry.
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5.3.4

AZA-PLGA-PEG Enables Better Targeting Efficiency against Breast Cancer in
Mouse Model

Similar to DAC-PLGA-PEG, AZA-PLGA-PEG showed a significantly improved cytotoxicity over free AZA in treating MCF7 breast cancer cells (Figure 5.13). As mentioned above, the primary obstacles in utilizing DNA demethylating agents to treat solid
tumors are the in vivo instability and rapid body clearance. To assess the bioavailability
of AZA-PLGA-PEG after circulation through the RES, peritoneal membrane, hepatic
portal system, and renal exclusion system, subcutaneously xenografted tumors with
MCF7 cells were established in mice. Eight doses of 1 mg/kg AZA-containing solution
were IP injected every two weeks when the body weight of mice was closely monitored
(Figure 5.14A). After four weeks’ treatment, free AZA showed minimal anti-tumor effect
whereas AZA-PLGA-PEG could constrain the tumor growth in a time-dependent manner
(Figure 5.14B). This in vivo experiment clearly demonstrates the superior bioavailability
of AZA-PLGA-PEG. Future study could be undertaken to optimize dosage regimens and
evaluate combination therapies for other solid tumors.
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Figure 5.13 Therapeutic effects using free AZA and AZA-PLGA-PEG nano-conjugate
against MCF7 cancer cells.
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Figure 5.14 In vivo anti-tumor activity of AZA-PLGA-PEG with improved drug stability
and bioavailability. (A) The body weight of mice was monitored to control severe side
effects. (B) The volume of xenografted tumors was recorded during the four-week treatment (n = 5).

5.4

Conclusion

This study aims to address a major problem with regard to drug delivery that has a
promising significance to popularize epigenetic therapies. To reach this goal, a nano-
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delivery system utilizing PLGA-PEG copolymer was developed and characterized. Upon
stabilizing the cytidine analogue drugs by conjugation, the formed nano-micelles feature
superior drug solubility, uptake efficiency, pH-dependent release, in vivo bioavailability,
and anti-proliferative potential. This work constitutes one of the very first to chemically
link the drug molecules to the PLGA backbone instead of physical encapsulation, therefore preventing unwanted burst release. By single-molecule fluorescence experiments the
rapid internalization and hydrolysis processes in an acidic cancer cell were quantitatively
monitored. In the proof-of-concept, DAC-PLGA-PEG was shown to potently sensitize
the chemo-resistant GBM cells to temozolomide by reactivation of the p53-p21 pathway.
AZA-PLGA-PEG achieved better in vivo efficacy targeting breast cancer xenografts in
comparison to free drug. Collectively, these results demonstrate the effectiveness of DNA
demethylating drugs in treating solid tumors when an appropriate delivery strategy is designed. Hence, this work is expected to be of translational potential to enrich the toolbox
of nanomedicine.
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CHAPTER 6. OPTOGENETIC TOOLS FOR EPIGENOME EDITING WITH SPATIOTEMPORAL PRECISION

6.1

Introduction

From the ENCODE and Roadmap Epigenomics projects, a huge number of epigenetic marks are statistically associated with specific phenotypes and diseases.97, 234 However,
in order to decode epigenetic language to mechanistic understanding in biology, tools
able to control loci-specific epigenetic states are needed. With respect to technical development, the ability to adjust epigenetic modification is also essential for drug screening,
disease modeling, epigenetic therapy, and developmental research. The first wave of
technical breakthrough came from the invention of agents that can globally change DNA
methylation and histone acetylation. Owing to those useful tools, our knowledge of environment-gene interaction, transcriptional regulation, phenotypic diversity, and cancer initiation has been elevated to a higher level. Moreover, some of the developments such as
cytidine analogues and histone deacetylase inhibitors have shown promising applications
in clinical medicine. Nevertheless, a grand challenge stagnating the first generation of
tools for epigenome editing is the limited spatiotemporal accuracy in that the majority of
singleplex causations could hardly be researched. In the last decade, loci-specific epigenome editing has been made possible thanks to the discovery of programmable DNAbinding molecules including ZFPs, TALEs, and CRISPR/Cas9 (detailed description in
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Chapter 1.2.4).235 These advances have sparked an explosion of revolution in biotechnology and single-cell engineering. By customizing a DNA-binding motif with an epigenetic
modifier, sequence-specific addition or removal of an epigenetic mark can be achieved in
individual cells.74, 75, 77, 80, 236, 237 From this moment, the methodologies for single-cell
manipulation are entering an era of nanoscale precision. On the basis of current techniques, this chapter aims to improve another aspect in loci-specific epigenome editing –
the temporal precision. By incorporating light-sensitive proteins into the epigenome editing machinery, the timing and extent of epigenetic modulation could be fine-tuned with a
standard light source, noninvasively.
The discoveries of the light-sensitive (optogenetic) proteins in plant and microbial
origin offer ample opportunities to manipulate the dynamic nature of gene expression
with spatiotemporal precision. CRY2-CIB1 and PHYB-PIF6 are representative optogenetic protein pairs and their heterodimerization can be activated by blue light and red
light, respectively.238, 239 Upon illumination by 390-480 nm light, CRY2 is photoactivated
to couple with CIB1 whereas the PHYB-PIF6 coupling is dependent on a 650-670 nm
illumination. Further, these light-inducible associations are reversible: CRY2-CIB1 will
automatically dissociate in the absence of light whilst PHYB-PIF6 needs an additional
infrared illumination (~750 nm) to detach.240, 241 The importance of optogenetic interaction was first recognized as in relation to flowering and circadian rhythms of plants.242, 243
Recently, genetically engineered molecular constructs containing CRY2-CIB1 or PHYBPIF6 have been used as novel means for subcellular localization and (epi)genome-editing
in a variety of contexts.81, 244-249 Yet, limited techniques are available to precisely quantify
an optogenetic reaction. Herein this present study demonstrates the feasibility of dynamic
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monitoring the interaction kinetics of CRY2-CIB1 and PHYB-PIF6 with single-molecule
fluorescence tools. Moreover, by constructing a pair of DNMT3A-CRY2-mCherry and
TRF1-CIB1-EGFP fusion proteins, this chapter provides the proof-of-concept for selective de novo DNA methylation at subtelomeric CpGs with tunable acquisition and temporal precision.

6.2
6.2.1

Methods and Materials

Preparation of Optogenetic Proteins

Plasmids encoding the optogenetic protein pairs were obtained from the Addgene
global plasmid repository (http://www.addgene.org/): pCRY2PHR(498 aa)-mCherryN1
(#26866), pCIB1(335 aa)-pmGFP (#28240), pCIBN(the N-terminal 170 aa from CIB1)pmGFP

(#26867),

pAL149

[pCMV-PHYB(1-908)-10aaLinker-mCherry-Kras4BCT

(#22275)], pAL175 [pSV40-mYFP-PIF6APB (#22276)]. Plasmids were transformed into
the stellar competent cells (PT-5056-2, Clontech) for amplification and selection. Extraction and purification of plasmid DNA was performed with QIAprep Spin Miniprep Kit
(Qiagen). The blue and red light-induced optogenetic associations were demonstrated in
HeLa cells transfected with proper protein pairs. For in vitro kinetics experiments, transfected cells were lysed by M-PER mammalian protein extraction reagent (Pierce), followed by acetone precipitation to remove lipid content. The concentration of fluorescent
optogenetic proteins in cell lysate was determined by FCS. The phycocyanobilin (PCB)
required for PHYB-PIF6 dimerization was extracted by methanolysis from Spirulina lysate. 5 µM PCB was added to the reaction buffer or cell culture medium when testing the
PHYB-PIF6 interaction.
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6.2.2

FCS for Measuring the CRY2-CIB1/N Binding Kinetics

A single blue laser-based FCS was used for measuring the in vitro CRY2-CIB1/N
binding kinetics. One prominent advantage of this approach is that the 465 nm picosecond pulsed excitation for GFP is also the peak wavelength to induce the CRY2-CIB1/N
dimerization. As the size of CRY2 is significantly larger than CIB1/N, the diffusion rate
of a free CIB1/N is much faster than that of a CRY2-CIB1/N complex. Hence, the twocomponent 3D diffusion model can be used to characterize the free and bound forms of
CIB1/N-GFP in a quantitative manner. Figure 6.1A outlines the experiment design: a 2030 µL of the sample droplet containing equimolar concentrations of CRY2-mCherry and
CIB1/N-GFP proteins is mounted to a humid microscopic chamber from which a timecourse fluorescence fluctuation trace is recorded. Along the blue laser excitation, monodispersed CRY2-mCherry and CIB1/N-GFP are expected to couple with each other. Due
to the high numeric aperture of the applied objective lens (focal length = 0.25 mm), the
excitation beam waist would rapidly expand below and above the focal plane so that the
majority of optogenetic proteins in the droplet can be efficiently photoactivated. Then the
obtained fluorescence fluctuation trace is segmented to several time windows and an autocorrelation function is generated from each interval. By fitting with the diffusion model
algorithm, the proportion of free and bound CIB1/N-GFP molecules at a specific time
point can be determined (Figure 6.1B).
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Figure 6.1 Scheme for measuring the CRY2-CIB binding kinetics by FCS. (A) The excitation profile for a sample droplet containing optogenetic proteins. A single blue laser is
used to excite GFP and in the meantime to induce the optogenetic association. (B) The
two-component 3D diffusion model is used to characterize the free and bound CIB molecules.

6.2.3

PIE-FLCS for Measuring the PHYB-PIF6 Binding Kinetics

In order to monitor the real-time PHYB-PIF6 binding kinetics, two illumination
sources were implemented. Here pulsed interleaved excitation-based fluorescence lifetime correlation spectroscopy (PIE-FLCS) was used to reduce photodamage and better
separate the single-molecule information of PIF6-YFP (Figure 6.2A). In PIE mode, the
red (for dimerization induction) and blue light pulses (for YFP excitation) are intermitted
by a 5 ns delay and the laser repetition rate is set to 40 MHz. Therefore, the peak energy
imposed on the sample is half of that under a synchronized excitation. Moreover, the red
laser-caused autofluorescence and background noises would radically decay in that 5 ns
gap period, which benefits a high signal-to-noise ratio (SNR) when collecting the YFP
signal (Figure 6.2B).
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Figure 6.2 Scheme for measuring the PHYB-PIF binding kinetics by PIE-FLCS. (A) The
excitation profile for a sample droplet containing optogenetic proteins. The blue laser is
for fluorescence detection and the red laser is for optogenetic induction. The PIE mode
intermits the laser pulses by 5 ns. (B) The SNR for PIF6-YFP is enhanced from the raw
fluorescence signals.

Figure 6.3 Changes in the diffusion rate and fluorescence lifetime of PIF6-YFP due to its
association with PHYB-mCherry.

During the PHYB-PIF6 coupling, two events occurring to PIF6-YFP can be used to
reflect the dimerization rate. First, the FCS diffusion curve of PIF6-YFP would shift from
a one-component mode to a two-component mode (Figure 6.3A). Second, the TCSPC
decay of PIF6-YFP would become steeper due to the FRET between YFP and mCherry
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(Figure 6.3B). Combining these two sets of information, quantities of the free and bound
PIF6-YFP can be precisely calculated.

6.2.4

Molecular Cloning of DNMT3A-CRY2-mCherry and TRF1-CIB1-EGFP

To demonstrate the loci-specific epigenome editing with optogenetic tools, two new
fusion proteins were constructed by molecular cloning. CRY2-mCherry and CIB1-EGFP
were fused to DNMT3A and TRF1, respectively. The coding sequences of DNMT3A
(#35521, Addgene), CRY2-mCherry, EGFP (#23027, Addgene), CIB1, and TRF1
(#16058, Addgene) were PCR amplified from individual templates and assembled to the
C-terminus of pHTN HaloTag CMV-neo Vector (Promega).
Sequence information:
>HaloTag-DNMT3A-linker-CRY2-mCherry (~223 kDa)
MAEIGTGFPFDPHYVEVLGERMHYVDVGPRDGTPVLFLHGNPTSSYVWRNIIPHVAPTH
RCIAPDLIGMGKSDKPDLGYFFDDHVRFMDAFIEALGLEEVVLVIHDWGSALGFHWAKR
NPERVKGIAFMEFIRPIPTWDEWPEFARETFQAFRTTDVGRKLIIDQNVFIEGTLPMGV
VRPLTEVEMDHYREPFLNPVDREPLWRFPNELPIAGEPANIVALVEEYMDWLHQSPVPK
LLFWGTPGVLIPPAEAARLAKSLPNCKAVDIGPGLNLLQEDNPDLIGSEIARWLSTLEI
SGEPTTEDLYFQSDNAIASEFGSANTGAMPAMPSSGPGDTSSSAAEREEDRKDGEEQEE
PRGKEERQEPSTTARKVGRPGRKRKHPPVESGDTPKDPAVISKSPSMAQDSGASELLPN
GDLEKRSEPQPEEGSPAGGQKGGAPAEGEGAAETLPEASRAVENGCCTPKEGRGAPAEA
GKEQKETNIESMKMEGSRGRLRGGLGWESSLRQRPMPRLTFQAGDPYYISKRKRDEWLA
RWKREAEKKAKVIAGMNAVEENQGPGESQKVEEASPPAVQQPTDPASPTVATTPEPVGS
DAGDKNATKAGDDEPEYEDGRGFGIGELVWGKLRGFSWWPGRIVSWWMTGRSRAAEGTR
WVMWFGDGKFSVVCVEKLMPLSSFCSAFHQATYNKQPMYRKAIYEVLQVASSRAGKLFP
VCHDSDESDTAKAVEVQNKPMIEWALGGFQPSGPKGLEPPEEEKNPYKEVYTDMWVEPE
AAAYAPPPPAKKPRKSTAEKPKVKEIIDERTRERLVYEVRQKCRNIEDICISCGSLNVT
LEHPLFVGGMCQNCKNCFLECAYQYDDDGYQSYCTICCGGREVLMCGNNNCCRCFCVEC
VDLLVGPGAAQAAIKEDPWNCYMCGHKGTYGLLRRREDWPSRLQMFFANNHDQEFDPPK
VYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCEDSITVGMVRHQGK
IMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFFEFYRLLH
DARPKEGDDRPFFWLFENVVAMGVSDKRDISRFLESNPVMIDAKEVSAAHRARYFWGNL
PGMNRPLASTVNDKLELQECLEHGRIAKFSKVRTITTRSNSIKQGKDQHFPVFMNEKED
ILWCTEMERVFGFPVHYTDVSNMSRLARQRLLGRSWSVPVIRHLFAPLKEYFACVGTSG
SLESGSTPAMKMDKKTIVWFRAMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFI
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WCPEEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGAT
KVVFNHLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYW
KKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSPGW
SNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWA
RDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWR
QGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLE
CDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHHPWD
APLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTREAQIMIGAAARDPPVATMVS
KGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFA
WDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDG
EFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDA
EVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK
>HaloTag-EGFP-linker-CIB1-NLS-linker-TRF1 (~149 kDa)
MAEIGTGFPFDPHYVEVLGERMHYVDVGPRDGTPVLFLHGNPTSSYVWRNIIPHVAPTH
RCIAPDLIGMGKSDKPDLGYFFDDHVRFMDAFIEALGLEEVVLVIHDWGSALGFHWAKR
NPERVKGIAFMEFIRPIPTWDEWPEFARETFQAFRTTDVGRKLIIDQNVFIEGTLPMGV
VRPLTEVEMDHYREPFLNPVDREPLWRFPNELPIAGEPANIVALVEEYMDWLHQSPVPK
LLFWGTPGVLIPPAEAARLAKSLPNCKAVDIGPGLNLLQEDNPDLIGSEIARWLSTLEI
SGEPTTEDLYFQSDNAIASEFMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDA
TYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQER
TIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMAD
KQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEK
RDHMVLLEFVTAAGITLGMDELYKALESGSTPAMNGAIGGDLLLNFPDMSVLERQRAHL
KYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPETT
LGTGNFKKRKFDTETKDCNEKKKKMTMNRDDLVEEGEEEKSKITEQNNGSTKSIKKMKH
KAKKEENNFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKFLQD
LVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVASTP
MTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCFNNGEAPSM
WDSHVQNLYGNLGVGTSVPAGSPKKKRKVEASGRDADPTEEQMAETERNDEEQFECQEL
LECQVQVGAPEEEEEEEEDAGLVAEAEAVAAGWMLDFLCLSLCRAFRDGRSEDFRRTRN
SAEAIIHGLSSLTACQLRTIYICQFLTRIAAGKTLDAQFENDERITPLESALMIWGSIE
KEHDKLHEEIQNLIKIQAIAVCMENGNFKEAEEVFERIFGDPNSHMPFKSKLLMIISQK
DTFHSFFQHFSYNHMMEKIKSYVNYVLSEKSSTFLMKAAAKVVESKRTRTITSQDKPSG
NDVEMETEANLDTRKRSHKNLFLSKLQHGTQQQDLNKKERRVGTPQSTKKKKESRRATE
SRIPVSKSQPVTPEKHRARKRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSV
MLKDRWRTMKKLKLISSDSED

6.2.5

Illumination for Selective Subtelomeric de novo DNA Methylation

In order to illuminate large populations of transfected cells for the downstream bisulfite-pyrosequencing, a mounted high-power LED with a peak wavelength of 455 nm and
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a DC2100 LED driver (Thorlabs) were applied. The illumination beam size was adjusted
to uniformly cover the surface area of culture vessels. After optimization, the illumination
power in all subsequent experiments was determined to be 1-2 mW/cm2.
The methylation state at the representative subtelomeric CpGs (selected from chromosomes 7q, 8q, 16p, 18p, 21q, and Xp) was quantified with bisulfite-pyrosequencing.
Extracted from treated cells, 600 ng genomic DNA was bisulfite converted with EZ DNA
Methylation Kit (Zymo Research) and then PCR-amplified against predetermined regions
using PyroMark PCR Kit (Qiagen). The PCR products were subjected to pyrosequencing
in a PyroMark Q24 system.
Table 6.1 Primers used for bisulfite-PCR. 5’-/5BiosG/ is the 5’-biotinylation tag on the
primers for subsequent pyrosequencing
Forward
7q
8q
16q
18q
21q
Xp

AGTGGATATTTAGGTTTATGATTGTAAT
TGTTTTTTTTTTTTTATTAAAAGGTGAGTT
GTTTTAATTGGTTTTTGATTTTGATTAT
5’-/BiosG/GTTGTGGTGTAGGTTTATAATTT
TTTTGGAGGATTGTGTTTAGATAGATAT
GTGGGTTAGTTTGTATTGAGGTAGGTAT

Reverse
5’-/BiosG/CTCCCCAAAAAACACTTTACTCTTTCACA
5’-/BiosG/AAAAATCTCCAAAAAACCCTTATAAAC
5’-/BiosG/CTCAACACAAACCTAAAAATCACC
ACCCCCAAAAAAAAACTACAAAAACC
5’-/5BiosG/CCCAACTCCTTCCAAATAAAT
5’-/5BiosG/AAAACCCCCTAACCCCTCC

Prod.
257
139
164
185
137
307

Table 6.2 Information of the sequenced regions and the sequencing primers. Y/R is the
potential methylated cytosine positions at the target CpGs
Sequenced region
7q
8q
16q
18q
21q
Xp

AAATTTGTTATYGTAGTGGTYGGATTTTTTTGGGTTATTYGAGTGGAGYGG
TYGGGTT
YGGGTAYGTAGTTAGYGTTYGYGATTATTYGTTTATAAGGGTTTTTT
AYGGTTGTAATYGGGAAAGATTTTATTTATTGTTAATGYGTTTYGAGTTGT
TTTAAAGTTAGGTAGTGTTTTTAAYGTTTGTGTTTAGTAGAATGTTGTTT
AACCRCCCTCRCAACCCAAATAACCRATTTATCCTACCCRAAAAACATCRC
CCTCCTCCRC
TTYGTAGGTGTGYGYGGYGTTYGTAAGTGGTTAGTATAAYGTYGGGYGAA
TYGAGGTGATTYGGGTGGGAGGTGTATYGTYGTTTATT

Sequencing primer
TTTATGATTGTAATTTTATAATA
ATTTTTATTAGGAAAGGTGT
ATTGGTTTTTGATTTTGATTATTT
CTAAACCCCCCCTTCTACCCCTA
GTTTAGATAGATATTGGTTTTTTTA
GAGGTAGGTATGGGT
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6.3
6.3.1

Results and Discussion

Demonstration of Optogenetic Association in Living Cells

First, the CRY2-CIB1 and PHYB-PIF6 mediated subcellular redistribution of tagged
proteins was demonstrated in living HeLa cells. The design principle was to localize one
part of the optogenetic pair at a specific cell compartment and then attract the complementary part to the same compartment with proper illumination. As shown in Figure
6.4A, TRF1-CIB1-EGFP predominantly locates in cell nucleus due to the presence of
TRF1 whereas CRY2-mCherry primarily distributes in cytoplasm. After 30 min illumination with blue light, CRY2-mCherry could be efficiently imported to nucleus because of
the optogenetic CRY2-CIB1 dimerization. In another demonstration, PHYB-mCherry is
pre-anchored to cell membrane by incorporating a Kras CAAX-motif to its sequence
while PIF6-YFP freely diffuses inside cells. After a short red illumination, PIF6-YFP experiences radical redistribution to cell membrane, validating the PHYB-PIF6 coupling
(Figure 6.4B). By comparing the YFP fluorescence in cytoplasm and on membrane, a reversion in relative intensity can be clearly seen after illumination. In consistence, the intracellular concentration of PIF6-YFP is reduced from 600 nM to 320 nM in a sampling
region. Furthermore, FLIM-FRET confirms the specific PHYB-PIF6 dimerization on cell
membrane as only an inter-protein distance below 10 nm can induce the non-radiative
energy transfer between YFP and mCherry (Figure 6.4C). Taken together, these experiments prove the effectiveness of optogenetic proteins as powerful tools to translocate biomolecules in human cells.
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Figure 6.4 Optogenetic associations in living HeLa cells. (A) TRF1-CIB1-EGFP recruits
cytoplasmic CRY2-mCherry to nucleus after blue illumination. (B) Membrane-anchored
PHYB-mCherry induces redistribution of PIF6-YFP after red illumination. FCS quantitatively confirms the reduction of PIF6-YFP in cytoplasm. (C) FLIM-FRET confirms the
specific association between PHYB-mCherry and PIF6-YFP on cell membrane.

6.3.2

In vitro CRY2-CIB1/N Binding Kinetics

Initially, fluorescence cross-correlation spectroscopy (FCCS) was proposed to be a
fitted technique to probe the CRY2-CIB1/N binding kinetics since they were separately
labeled with different fluorescence proteins. However, it was reported that the activity of
cryptochrome could be impacted by green irradiation to some extent. A green-to-yellow
excitation would suppress the equilibrium of flavin redox critical for CRY2 activation
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and thus retard its optogenetic association with CIB1.250, 251 To avoid this possible negative effect, a single blue laser-based FCS was applied.
In a 20 µL reaction droplet containing 1 nM CRY2-mCherry and CIB1/N-GFP, fluorescence fluctuation was recorded for 300 s and one autocorrelation function was generated from each 50 s time window. In Figure 6.5, a right-shift of the autocorrelation functions was observed for both combinations, indicating more bound proteins being formed
along the illumination. By fitting with two-component 3D diffusion model, the free and
bound protein components were determined. Compared to CIB1-GFP, CIBN-GFP possesses a faster diffusion rate (i.e., a larger diffusion coefficient) due to its smaller size
(Figure 6.6A): 59.77 ± 6.11 µm2/s versus 44.11 ± 4.13 µm2/s in free form, and 2.59 ±
0.62 µm2/s versus 2.19 ± 0.53 µm2/s in bound form. According to a recent study, CYR2
per se would be self-clustering under blue illumination in addition to dimerizing with
CIB1,252, 253 which explains why the observed changes in diffusion coefficient from free
to bound CIB1/N do not support a 1:1 binding stoichiometry with CRY2. However, the
fast mobility of CIBN was found not to increase its coupling efficiency with CRY2 in
vitro (Figure 6.6B). During the 300 s detection window, CIB1 yielded about 15% more
bound component than CIBN. This phenomenon implies that a less active diffusion is
conducive to stabilize the CRY2-CIB1 dimerization and the C-terminal 165 amino acids
in CIB1 may be required to facilitate the association kinetics. Furthermore, the excitation
power-dependent optogenetic association was observed (Figure 6.6B, inset). Overall, this
study provides the first quantitative evidence showing that CIB1 is better than CIBN as
the optogenetic complement to CRY2.
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Figure 6.5 In vitro association kinetics of CIB1-CRY2 and CIBN-CRY2 probed by FCS.

Figure 6.6 Characterization of the CRY2-CIB association rate. (A) Diffusion coefficients
of free and bound CIB1/N-GFP (n = 9, mean + S.E.M.). (B) The incremental percentage
of bound CIB1/N-GFP in a 300 s detection window (n = 5).

6.3.3

In vitro PHYB-PIF6 Binding Kinetics

As perceived from the preliminary cell experiments, the PHYB-PIF6 dimerization
occurs much faster than CRY2-CIB1. Therefore, in this part, fluorescence lifetime was
included in analysis to better characterize the free and bound PIF6-YFP. A 50 µL reaction droplet containing 100 nM PHYB-mCherry and PIF6-YFP was mounted for PIE il-
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lumination. Two methods were used to determine the percentage of free/bound PIF6-YFP
at a specific time point. In the TCSPC method, the bound form of PIF6-YFP is distinguished from the free form based on the occurrence of FRET. According to the law of

 t 
fluorescence decay: I (t ) = I 0 ∑ ai exp  −  + c , the sum TCSPC histogram can be dei
 τi 
composed to three components: the bound (FRET) component, the free (non-FRET)
component, and the background (Figure 6.7A). By integrating the photon counts under
each component, the percentage of bound proteins can be calculated at a resolution of 1 s
(Figure 6.7B). In the second method, more sensitive FLCS is used to precisely determine
the concentration of free/bound PIF6-YFP. The differential decay patterns of FRET and
non-FRET PIF6-YFP make it possible to generate a TCSPC filter function to weigh the
possibility of a detected single photon from which component (Figure 6.8A). With this
filter function, a fluorescence lifetime-dependent autocorrelation function can be extracted by FLCS. Hence, featuring a steady fluorescence lifetime, photons from non-FRET
PIF6-YFP are separated. Autocorrelation functions are established from each 5 s time
window and the concentration information of free PIF6-YFP is obtained (Figure 6.8B).
These two methods have their own advantages and in the meantime complement each
other: the TCSPC decomposition provides a delicate temporal resolution and FLCS bring
about an excellent accuracy, which together uncover the dynamic PHYB-PIF6 interaction.
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Figure 6.7 TCSPC method for measuring the PHYB-PIF6 binding kinetics. (A) Mathematical decomposition of the sum TCSPC. (B) The association rate of PHYB-PIF6 is calculated by reassigning the photon counts to each lifetime component (n = 5).

Figure 6.8 FLCS method for determining the concentration of free PIF6-YFP. (A) Based
on differential fluorescence lifetimes a filter function is generated to extract photons from
the free component. (B) The concentration of free PIF6-YFP is determined by fitting the
FLCS autocorrelation functions at each time point.

When comparing the CRY2-CIB1 and PHYB-PIF6 binding kinetics, PHYB-PIF6
exhibits a much more efficient association. For 50% of proteins to get optogenetically
coupled, CRY2-CIB1 takes ~250 s whereas PHYB-PIF6 only needs ~5 s, which awaits
future research to investigate the underlying mechanisms. One possible explanation could
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be related to their functions in plants. Plants heavily rely on these two classes of optogenetic proteins to sense the blue and red wavelengths from sunlight. Considering the fact
that blue light has a higher energy than red light, optogenetic proteins responding to the
red wavelength might have evolved to gain a better photosensitivity. However, the additional demand for PCB impedes an extensive utilization of the PHYB-PIF6 pair in biological engineering.

6.3.4

Optogenetic Induction of Subtelomeric de novo DNA Methylation

Next, two constructs expressing TRF1-CIB1-EGFP and DNMT3A-CRY2-mCherry
were introduced to HeLa cells for demonstration of a light-inducible, loci-specific epigenome editing. TRF1-CIB1-EGFP serves as the targeting component to localize the enzymatic reaction of DNMT3A-CRY2-mCherry at subtelomeric regions (Figure 6.9A). Upon transient expression, TRF1-CIB1-EGFP shows a punctate distribution in cell nucleus,
highlighting the telomere positions (Figure 6.9B). From FCS measurements, two distinct
components were detected: a fast-diffusing free form (D = 5.96 ± 0.58 µm2/s) and a slowdiffusing bound form (D = 0.92 ± 0.08 µm2/s). A remarkably high percentage of bound
form of TRF1-CIB1-EGFP was noted inside those punctate spots (83 ± 17%). In contrast,
Nuc-GFP molecules predominantly exist as a free-diffusing form in whole nucleus (D =
11.23 ± 2.06 µm2/s). To further confirm the binding specificity of TRF1-CIB1-EGFP to
telomeric regions, a co-immunofluorescence staining for endogenous TRF2 proteins was
performed and the co-localization between TRF1-CIB1-EGFP and TRF2-Alexa647 was
unambiguously observed (Figure 6.9C). These results support that the constructed TRF1-
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CIB1-EGFP successfully recognizes the characteristic TTAGGG repeats in telomeric and
subtelomeric regions.254
Then the blue light-induced association of TRF1-CIB1-EGFP and DNMT3A-CRY2mCherry was assessed by FLIM-FRET. In control cells, the average fluorescence time of
EGFP was determined to be 2.41 ns (Figure 6.10A). On the other hand, the average fluorescence lifetime of EGFP in co-transfected cells was continuously decreased under blue
illumination. A 15% reduction in the EGFP fluorescence lifetime was achieved in 5 min
at an energy level of 8 mW/cm2 (Figure 6.10B). This significantly shortened fluorescence
lifetime is attributed to the FRET effect between EGFP and mCherry in the optogenetic
pair. In the following optimization, the association rate was found to be tunable by the
light intensity, for instance, an energy level of 1 mW/cm2 giving rise to a similar FRET
response in about 10 min. These data were validated with Co-IP experiments using EGFP
antibody and western blot using DNMT3A antibody. From the illuminated cell lysate,
DNMT3A-CRY2-mCherry could be co-immunoprecipitated by EGFP antibody (data not
shown). Collectively, this set of experiments proves the formation of TRF1-CIB1-EGFP
and DNMT3A-CRY2-mCherry complex at the desired loci after blue light illumination.
After the blue light-mediated re-localization of DNMT3A-CRY2-mCherry to chromosomal ends, the de novo methylase activity of DNMT3A is expected to increase the
DNA methylation levels at subtelomeric CpGs since no CpGs exist in telomeric regions
(Figure 6.11A). Six subtelomeric regions containing a number of CpGs were selected for
bisulfite-pyrosequencing after varied illumination durations. The pyrosequencing results
corroborate the blue light-induced increase in methylation at most of the CpGs. In general,
a longer light exposure results in more de novo methylation (Figure 6.11B). For example,
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with 4 h illumination the following changes occur: 12% increase at the 2nd CpG site of
Chr. 7, 7% increase at the 1st CpG site of Chr. 8q, 9% increase at the 1st CpG site of Chr.
16p, 19% increase at the 2nd CpG site of Chr. 18p, 5% increase at the 8th CpG site of Chr.
21q, and 12% increase at the 3rd CpG site of Chr. Xp. This substantial de novo methylation fully demonstrates the efficacy of optogenetic tools even in a short time. The differential increases for each CpG position could be ascribed to their different starting methylation levels and varying distance to the nearest TTAGGG repeat.255, 256 Admittedly,
some slight non-specific de novo methylation was noted (i.e., an increase in methylation
with 0 h illumination) due to the catalytic action of DNMT3A. However, in a selected
centromeric control region, no additional increase in methylation was observed upon cell
exposure to blue light. Hence, this line of research demonstrates the feasibility of locispecific epigenome editing with spatiotemporal precision enabled by optogenetic tools.
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Figure 6.9 Localization of TRF1-CIB1-EGFP to telomeric and subtelomeric regions. (A)
Design of the fusion protein. (B) The distribution and diffusion characteristics of TRF1CIB1-EGFP in nucleus. (C) Co-localization between TRF1-CIB1-EGFP and endogenous
TRF2.
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Figure 6.10 Blue light-induced re-localization of DNMT3A-CRY2-mCherry to telomeric
regions. (A) FLIM measurement for HeLa cells transfected with TRF1-CIB1-EGFP. (B)
FLIM measurement for cells co-transfected with TRF1-CIB1-EGFP and DNMT3ACRY2-mCherry under blue illumination.
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Figure 6.11 Blue light-induced de novo DNA methylation at the subtelomeric CpGs. (A)
Scheme of the working mechanism for optogenetic induction. (B) Analysis of changes in
DNA methylation at the selected CpG positions of six chromosomes.

6.4

Conclusion

Optogenetic protein pairs are emerging as a group of powerful tools in single-cell bioengineering. However, for a better implementation of these photosensitive molecules,
quantitative information regarding their associations is needed. In this chapter for the first
time the real-time binding kinetics of CRY2-CIB and PHYB-PIF, the major optogenetic
pairs responding to blue and red lights, is adequately characterized. By adapting singlemolecule fluorescence techniques including FCS, FLIM-FRET, TCSPC, and PIE-FLCS,
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optogenetic associations can be quantified with a subsecond resolution. Furthermore, this
study contributes to the pioneering efforts aimed to realize an on-demand, loci-specific
epigenome editing. By constructing DNA-targeting and epigenetic-effecting proteins that
can be photoactivated to function in predetermined sites, de novo DNA methylation was
successfully achieved at subtelomeric CpGs. Hence this work provides a novel, noninvasive method to manipulate epigenetic state and offers a unique avenue for epigenetic research. In addition, the diversity of the available optogenetic tools makes it possible to
multiplexing epigenome editing. Last but not least, in vivo application of optogenetic
tools is anticipated if advanced illumination facilities such as endoscopic multi-photon
excitation are integrated.
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CHAPTER 7. CONCLUDING REMARKS AND FUTURE PERSPECTIVES

During the historical transition from the superstitious astrology and alchemy to the
modern physics and chemistry, quantitative detection and utilization of mechanical forces,
electricity, light, chemical structures, and reaction kinetics have resulted in revolutionary
advances. Today, in order to decipher the epigenetic code in a single cell at the singlemolecule level, nanoscale measurements and engineering of various biomolecules and
activities hold the key. In conventional molecular biology, methods like electrophoresis,
PCR, and immunoassays heavily rely on ensemble results estimated from a population of
cells, thus overlooking the cellular heterogeneity and dynamic intermediates. In light of
advanced optical tools and nanotechnology, scrutinizing the epigenetic network with high
spatiotemporal resolutions is made possible and provides us with new dimensions to interpret life and diseases.
Metazoan species, especially human being, contains billions of variedly differentiated cells playing the fundamental roles in every biological process. For cells within the
same tissue or organ, at a given time point they might have distinct morphological traits
and functional states that are substantially dictated by epigenetic modulations. Single-cell
and single-molecule techniques offer us tremendous opportunities to inspect subcellular
components with unparalleled sensitivity and specificity. Advanced optics and nanoscale
engineering are particularly advantageous in characterizing the epigenetic conservation
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and variations implicated in dynamic biological systems. Moreover, the fast evolving and
enriching nanobiotechnology will not only benefit the basic research but also hold great
promise in healthcare practices.

Figure 7.1 Content composition of this dissertation.

My dissertation work aims to dissect the DNA methylation-related molecules and
events at the nanoscale using single-molecule detection techniques and nano-engineering
approaches (Figure 7.1). My research theme can be summarized to two major aspects:
characterization and manipulation. With regard to analytical characterization, my study
takes a unique route to quantitatively examine DNA methylation, i.e., via monitoring the
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DNA methylation-associated proteins. In Chapter 2, for the first time the dynamic process of active DNA demethylation is successfully correlated with the millisecond-level
mobility of MBD3, providing a novel strategy to inspect the global hypomethylation in
cancer. In Chapter 3, single-molecule fluorescence tools are further employed to explore
the binding preference, real-time association, and stoichiometric transition of MBD3 in a
single cell cycle, which constitutes a pioneering effort to analyze the intricacy of DNA
methylation homeostasis in single living cells. The results of my study reveal a crucial
role of MBD3 in the inheritance of DNA methylation. Inspired by these new findings, in
Chapter 4 I have conducted a translational study to delineate the regulatory network by
MBD3 in human malignant glioma and established it as a possible prognostic biomarker.
With exciting discoveries accumulated, I am fully convinced that single-cell and singlemolecule techniques unleash the power for us to better assess epigenetic mechanisms in a
micron-sized human cell, therefore complementing the future wave of precision medicine.
The other focus of my dissertation lies in controlling DNA methylation with nanoscale
accuracy and tunability. In Chapter 5, a novel PLGA-PEG-based di-block polymeric
nano-vector is developed to deliver the DNA demethylation drugs, and this formulation
features significant improvements on the aqueous stability, in vivo bioavailability, cell
uptake efficiency, pH-dependent release, and anti-proliferative potential. Other than the
global reshaping with DNA demethylation agents, in Chapter 6 the loci-specific epigenome editing using optogenetic proteins is demonstrated. Compared to the first generation of epigenome-editing methodologies, the tools developed herein add another layer of
modulation: i.e., the epigenetic status of a specific region can be adjusted on demand with
high temporal controllability. Taken together, this dissertation delivers a comprehensive
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toolbox for epigenetic research involving DNA methylation and unearths a number of
intracellular phenomena inaccessible by traditional means.
Admittedly, a variety of properties with respect to single-cell probing and singlemolecule engineering need further optimization. First, to achieve high-throughput readout
from most single-molecule techniques is a grand challenge since the trade-off between
the detection speed and precision limits the number of assessed targets at a time. Incorporation of the single-molecule analysis to the workflow of flow cytometry could be a possible solution. Second, so far even though numerous single-cell datasets have been obtained, a large proportion of them were from in vitro or ex vivo conditions. It is more imperative to interpret the behaviors of a single cell within its in vivo context. More efforts
for whole-body implementation of the newly developed tools such as fluorescence fluctuation spectroscopy, fluorescence lifetime imaging, single-photon counting, optogenetics,
and epigenome editing remain to be invested. Third, fully nontoxic and biocompatible
nanomaterials are still scarce at present. Therefore, utilization of synthetic biomaterials
including peptide nanosensors, xeno-nucleic acids, and DNA origami might be the future
options. Last but not least, to correlate the microscale genotype with the macroscale phenotype in epigenetics requires a combinatorial elucidation of the central dogma in biology.
With the advent of single-cell sequencing techniques, the hope of obtaining quantitative
information of DNA and RNA from a trace amount of cells is becoming a reality. Hence,
further research in understanding the epigenetic intricacy and its regulatory impact in a
loci-specific manner can be expected.
The biggest challenge begets the best work. Single-cell and single-molecule studies
are not commonplace in biomedicine yet but only a fraction of the possibilities, if any
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have been explored. Opportunities abound in enhancing our knowledge of embryogenesis,
development, aging, metabolic disorders, degenerative diseases, and cancer – the solution
to all our unsolved questions exclusively hinges upon the extent we know about and manipulate the function of a single cell, in which millions of actions occur in the timescale
ranging from nanoseconds to hours.
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